Dentsply 10-Q (1)


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 10-Q
 
x   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended June 30, 2012
OR
 
o    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from ______________ to _______________
 
Commission File Number 0-16211
 
DENTSPLY International Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
39-1434669
(State or other jurisdiction of
 
(I.R.S. Employer
incorporation or organization)
  
Identification No.)
 
221 West Philadelphia Street, York, PA
 
17405-0872
(Address of principal executive offices)
  
(Zip Code)
 
(717) 845-7511
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes   x No   o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes   x No   o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer” and “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  x
Accelerated filer  o
Non-accelerated filer  o
Smaller reporting company  o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   

Yes   o No   x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:  At July 27, 2012, DENTSPLY International Inc. had 141,784,960 shares of Common Stock outstanding, with a par value of $.01 per share.




DENTSPLY International Inc.

TABLE OF CONTENTS
 
 
 
Page
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

2



PART I – FINANCIAL INFORMATION

Item 1 – Financial Statements

DENTSPLY INTERNATIONAL INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(unaudited)

 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2012
 
2011
 
2012
 
2011
 
 
 
 
 
 
 
 
Net sales
$
762,994

 
$
609,443

 
$
1,479,407

 
$
1,179,946

Cost of products sold
355,525

 
294,592

 
679,188

 
565,111

 
 
 
 
 
 
 
 
Gross profit
407,469

 
314,851

 
800,219

 
614,835

Selling, general and administrative expenses
296,034

 
210,984

 
600,388

 
411,751

Restructuring and other costs
2,528

 
6,863

 
3,765

 
7,496

 
 
 
 
 
 
 
 
Operating income
108,907

 
97,004

 
196,066

 
195,588

 
 
 
 
 
 
 
 
Other income and expenses:
 

 
 

 
 

 
 

Interest expense
14,584

 
5,570

 
30,366

 
11,913

Interest income
(2,011
)
 
(2,430
)
 
(4,308
)
 
(4,258
)
Other expense (income), net
748

 
1,434

 
1,230

 
1,504

 
 
 
 
 
 
 
 
Income before income taxes
95,586

 
92,430

 
168,778

 
186,429

Provision for income taxes
14,875

 
17,957

 
29,590

 
41,669

Equity in net earnings (loss) of unconsolidated affiliated company
1,329

 
917

 
(2,919
)
 
93

 
 
 
 
 
 
 
 
Net income
82,040

 
75,390

 
136,269

 
144,853

Less: Net income attributable to noncontrolling interests
1,276

 
1,154

 
2,220

 
1,533

 
 
 
 
 
 
 
 
Net income attributable to DENTSPLY International
$
80,764

 
$
74,236

 
$
134,049

 
$
143,320

 
 
 
 
 
 
 
 
Earnings per common share:
 

 
 

 
 

 
 

Basic
$
0.57

 
$
0.53

 
$
0.95

 
$
1.01

Diluted
$
0.56

 
$
0.52

 
$
0.93

 
$
1.00

 
 
 
 
 
 
 
 
Weighted average common shares outstanding:
 

 
 

 
 

 
 

Basic
141,737

 
141,052

 
141,729

 
141,331

Diluted
143,863

 
143,373

 
143,908

 
143,694


See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

3




DENTSPLY INTERNATIONAL INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands)
(unaudited)

 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2012
 
2011
 
2012
 
2011
 
 
 
 
 
 
 
 
Net income
$
82,040

 
$
75,390

 
$
136,269

 
$
144,853

 
 
 
 
 
 
 
 
Other comprehensive (loss) income, net of tax:
 
 
 
 
 
 
 
Foreign currency translation adjustments
(178,746
)
 
62,051

 
(45,275
)
 
152,767

Net gain (loss) on derivative financial instruments
47,089

 
(36,391
)
 
14,957

 
(63,403
)
Net unrealized holding (loss) gain on available-for-sale securities
(7,954
)
 
(6,233
)
 
15,046

 
(2,031
)
Pension liability adjustments
1,726

 
(1,500
)
 
1,666

 
(2,033
)
Total other comprehensive (loss) income
(137,885
)
 
17,927

 
(13,606
)
 
85,300

 
 
 
 
 
 
 
 
Total comprehensive (loss) income
(55,845
)
 
93,317

 
122,663

 
230,153

 
 
 
 
 
 
 
 
Less: Comprehensive (loss) income attributable
 

 
 

 
 

 
 

to noncontrolling interests
(928
)
 
3,833

 
1,356

 
7,476

 
 
 
 
 
 
 
 
Comprehensive (loss) income attributable to
 
 
 
 
 
 
 
DENTSPLY International
$
(54,917
)
 
$
89,484

 
121,307

 
222,677

 


 


 


 



See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

4




DENTSPLY INTERNATIONAL INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except per share amounts)
(unaudited)
 
June 30, 2012
 
December 31, 2011
Assets
 
 
 
Current Assets:
 
 
 
Cash and cash equivalents
$
53,210

 
$
77,128

Accounts and notes receivables-trade, net
462,233

 
427,709

Inventories, net
403,195

 
361,762

Prepaid expenses and other current assets
186,544

 
146,304

 
 
 
 
Total Current Assets
1,105,182

 
1,012,903

 
 
 
 
Property, plant and equipment, net
587,285

 
591,445

Identifiable intangible assets, net
947,747

 
791,100

Goodwill, net
2,036,084

 
2,190,063

Other noncurrent assets, net
194,458

 
169,887

 
 
 
 
Total Assets
$
4,870,756

 
$
4,755,398

 
 
 
 
Liabilities and Equity
 

 
 

Current Liabilities:
 

 
 

Accounts payable
$
145,850

 
$
149,117

Accrued liabilities
347,906

 
289,201

Income taxes payable
12,646

 
9,054

Notes payable and current portion of long-term debt
241,801

 
276,701

 
 
 
 
Total Current Liabilities
748,203

 
724,073

 
 
 
 
Long-term debt
1,482,783

 
1,490,010

Deferred income taxes
334,673

 
249,822

Other noncurrent liabilities
316,098

 
407,342

 
 
 
 
Total Liabilities
2,881,757

 
2,871,247

 
 
 
 
Commitments and contingencies


 


 
 
 
 
Equity:
 

 
 

Preferred stock, $.01 par value; .25 million shares authorized; no shares issued

 

Common stock, $.01 par value; 200.0 million shares authorized; 162.8 million shares issued at June 30, 2012 and December 31, 2011.
1,628

 
1,628

Capital in excess of par value
230,862

 
229,687

Retained earnings
2,654,044

 
2,535,709

Accumulated other comprehensive loss
(203,712
)
 
(190,970
)
Treasury stock, at cost, 21.0 million and 21.1 million shares at June 30, 2012 and December 31, 2011, respectively.
(731,253
)
 
(727,977
)
Total DENTSPLY International Equity
1,951,569

 
1,848,077

 
 
 
 
Noncontrolling interests
37,430

 
36,074

 
 
 
 
Total Equity
1,988,999

 
1,884,151

 
 
 
 
Total Liabilities and Equity
$
4,870,756

 
$
4,755,398


See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

5



DENTSPLY INTERNATIONAL INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(unaudited)
 
Six Months Ended
June 30,
 
2012
 
2011
Cash flows from operating activities:
 
 
 
 
 
 
 
Net income
$
136,269

 
$
144,853

 
 
 
 
Adjustments to reconcile net income to net cash provided by operating activities:
 

 
 

Depreciation
40,357

 
32,359

Amortization
28,014

 
4,736

Amortization of deferred financing costs
2,391

 

Deferred income taxes
(4,432
)
 
6,894

Share-based compensation expense
11,029

 
10,316

Restructuring and other costs - noncash
2,105

 
(787
)
Stock option income tax benefit
(5,163
)
 
(6,217
)
Net interest expense on derivatives with an other-than-insignificant financing element
1,135

 
1,545

Equity in earnings from unconsolidated affiliates
2,919

 
(93
)
Other non-cash expense
(4,237
)
 
(955
)
Changes in operating assets and liabilities, net of acquisitions:
 

 
 

Accounts and notes receivable-trade, net
(41,461
)
 
(40,357
)
Inventories, net
(47,034
)
 
(8,368
)
Prepaid expenses and other current assets
(19,455
)
 
(1,927
)
Other noncurrent assets, net
(3,497
)
 
(4,519
)
Accounts payable
(1,320
)
 
4,129

Accrued liabilities
(3,244
)
 
9,051

Income taxes payable
5,423

 
12,942

Other noncurrent liabilities
3,596

 
2,907

 
 
 
 
Net cash provided by operating activities
103,395

 
166,509

 
 
 
 
Cash flows from investing activities:
 

 
 

 
 
 
 
Capital expenditures
(42,986
)
 
(25,338
)
Cash paid for acquisitions of businesses, net of cash acquired

 
(20,087
)
Payments on settlements of net investment hedges
(14,221
)
 

Expenditures for identifiable intangible assets
(188
)
 
(332
)
Purchase of Company-owned life insurance policies
(1,577
)
 

Proceeds from sale of property, plant and equipment, net
465

 
175

 
 
 
 
Net cash used in investing activities
(58,507
)
 
(45,582
)
 
 
 
 
Cash flows from financing activities:
 

 
 

 
 
 
 
Net change in short-term borrowings
(35,181
)
 
(177
)
Cash paid for treasury stock
(38,840
)
 
(79,500
)
Cash dividends paid
(15,706
)
 
(14,312
)
Cash paid for contingent consideration on prior acquisitions
(1,781
)
 
(1,780
)
Cash paid for acquisition of noncontrolling interests of consolidated subsidiaries

 
(16,431
)
Proceeds from long-term borrowings

 
38,254

Repayments of long-term borrowings

 
(2,403
)
Payment on terminated derivative instruments

 

Proceeds from exercise of stock options
20,066

 
33,993

Excess tax benefits from share-based compensation
5,163

 
6,217

Net interest payments on derivatives with an other-than-insignificant financing element
(1,135
)
 
(1,545
)
 
 
 
 
Net cash used in financing activities
(67,414
)
 
(37,684
)
 
 
 
 
Effect of exchange rate changes on cash and cash equivalents
(1,392
)
 
48,429

 
 
 
 
Net (decrease) increase in cash and cash equivalents
(23,918
)
 
131,672

 
 
 
 
Cash and cash equivalents at beginning of period
77,128

 
540,038

 
 
 
 
Cash and cash equivalents at end of period
$
53,210

 
$
671,710

 
See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

6



DENTSPLY INTERNATIONAL INC. AND SUBSIDIARIES
CONSOLIDATED STATMENTS OF CHANGES IN EQUITY
(In thousands)
(unaudited)

 
Common
Stock
 
Capital in
Excess of
Par Value
 
Retained
Earnings
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Treasury
Stock
 
Total DENTSPLY
International
Equity
 
Noncontrolling
Interests
 
Total
Equity
Balance at December 31, 2010
$
1,628

 
$
204,902

 
$
2,320,350

 
$
24,156

 
$
(711,650
)
 
$
1,839,386

 
$
70,526

 
$
1,909,912

 
 

 
 

 
 

 
 

 
 

 
 

 
 

 
 

Net income

 

 
143,320

 

 

 
143,320

 
1,533

 
144,853

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other comprehensive income
 

 
 

 
 

 
79,357

 
 

 
79,357

 
5,943

 
85,300

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acquisition of noncontrolling interest

 
22,394

 

 

 

 
22,394

 
(38,825
)
 
(16,431
)
Exercise of stock options

 
(11,578
)
 

 

 
45,571

 
33,993

 

 
33,993

Tax benefit from stock options exercised

 
6,217

 

 

 

 
6,217

 

 
6,217

Share based compensation expense

 
10,362

 

 

 

 
10,362

 

 
10,362

Funding of Employee Stock Ownership Plan

 
379

 

 

 
2,595

 
2,974

 

 
2,974

Treasury shares purchased

 

 

 

 
(79,500
)
 
(79,500
)
 

 
(79,500
)
Dividends paid by noncontrolling interest

 

 

 

 

 

 
(174
)
 
(174
)
RSU distributions

 
(5,696
)
 

 

 
3,539

 
(2,157
)
 

 
(2,157
)
RSU dividends

 
91

 
(91
)
 

 

 

 

 

Cash dividends ($0.10 per share)

 

 
(14,116
)
 

 

 
(14,116
)
 

 
(14,116
)
Balance at June 30, 2011
$
1,628

 
$
227,071

 
$
2,449,463

 
$
103,513

 
$
(739,445
)
 
$
2,042,230

 
$
39,003

 
$
2,081,233


 
Common
Stock
 
Capital in
Excess of
Par Value
 
Retained
Earnings
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Treasury
Stock
 
Total DENTSPLY
International
Equity
 
Noncontrolling
Interests
 
Total
Equity
Balance at December 31, 2011
$
1,628

 
$
229,687

 
$
2,535,709

 
$
(190,970
)
 
$
(727,977
)
 
$
1,848,077

 
$
36,074

 
$
1,884,151

 
 

 
 

 
 

 
 

 
 

 
 

 
 

 
 

Net income

 

 
134,049

 

 

 
134,049

 
2,220

 
136,269

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other comprehensive loss

 

 

 
(12,742
)
 

 
(12,742
)
 
(864
)
 
(13,606
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exercise of stock options

 
(7,158
)
 

 

 
27,224

 
20,066

 

 
20,066

Tax benefit from stock options exercised

 
5,163

 

 

 

 
5,163

 

 
5,163

Share based compensation expense

 
11,029

 

 

 

 
11,029

 

 
11,029

Funding of Employee Stock Ownership Plan

 
370

 

 

 
3,272

 
3,642

 

 
3,642

Treasury shares purchased

 

 

 

 
(38,840
)
 
(38,840
)
 

 
(38,840
)
RSU distributions

 
(8,344
)
 

 

 
5,068

 
(3,276
)
 

 
(3,276
)
RSU dividends

 
115

 
(115
)
 

 

 

 

 

Cash dividends ($0.11 per share)

 

 
(15,599
)
 

 

 
(15,599
)
 

 
(15,599
)
Balance at June 30, 2012
$
1,628

 
$
230,862

 
$
2,654,044

 
$
(203,712
)
 
$
(731,253
)
 
$
1,951,569

 
$
37,430

 
$
1,988,999


See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

7



DENTSPLY International Inc. and Subsidiaries

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules of the United States Securities and Exchange Commission (“SEC”).  The year-end consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by US GAAP. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year. These financial statements and related notes contain the accounts of DENTSPLY International Inc. and Subsidiaries (“DENTSPLY” or the “Company”) on a consolidated basis and should be read in conjunction with the consolidated financial statements and notes included in the Company’s most recent Form 10-K for the year ended December 31, 2011.

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES

The accounting policies of the Company, as applied in the interim consolidated financial statements presented herein are substantially the same as presented in the Company’s Form 10-K for the year ended December 31, 2011, except as may be indicated below:

Accounts and Notes Receivable

The Company sells dental and certain healthcare products through a worldwide network of distributors and directly to end users.  For customers on credit terms, the Company performs ongoing credit evaluations of those customers' financial condition and generally does not require collateral from them.  The Company establishes allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments based on historical averages of aged receivable balances and the Company’s experience in collecting those balances, customer specific circumstances, as well as changes in the economic and political environments.  The Company records a provision for doubtful accounts, which is included in “Selling, general and administrative expenses.”

Accounts and notes receivables – trade, net are stated net of allowances for doubtful accounts and trade discounts, which was $13.7 million at June 30, 2012 and $15.8 million at December 31, 2011.

Marketable Securities

The Company’s marketable securities consist of corporate convertible bonds that are classified as available-for-sale in “Other noncurrent assets, net” on the consolidated balance sheets as the instruments mature in December 2015. The Company determined the appropriate classification at the time of purchase and will re-evaluate such designation as of each balance sheet date. In addition, the Company reviews the securities each quarter for indications of possible impairment. Once identified, the determination of whether the impairment is temporary or other-than-temporary requires significant judgment. The primary factors that the Company considers in classifying the impairment include the extent and time the fair value of each investment has been below cost and the existence of a credit loss. If a decline in fair value is judged other-than-temporary, the basis of the securities is written down to fair value and the amount of the write-down is included as a realized loss. Changes in fair value are reported in accumulated other comprehensive income (“AOCI”).

 The convertible feature of the bonds has not been bifurcated from the underlying bonds as the feature does not contain a net-settlement feature, nor would the Company be able to achieve a hypothetical net-settlement that would substantially place the Company in a comparable cash settlement position.  As such, the derivative is not accounted for separately from the bond.  The cash paid by the Company was equal to the face value of the bonds issued, and therefore, the Company has not recorded any bond premium or discount on acquiring the bonds.  The fair value of the bonds was $68.4 million and $47.8 million at June 30, 2012 and December 31, 2011, respectively.  At June 30, 2012 and December 31, 2011, an unrealized holding gain of $22.0 million and $11.5 million, respectively, on available-for-sale securities, net of tax, had been recorded in AOCI. 

New Accounting Pronouncements

In June 2011, the Financial Accounting Standards Board (“FASB”) amended its rules regarding the presentation of comprehensive income.  The objective of this amendment is to improve the comparability, consistency and transparency of financial reporting and to increase the prominence of items reported in other comprehensive income.  Specifically, this amendment requires that all non-owner changes in shareholders' equity be presented either in a single continuous statement of comprehensive income

8



or in two separate but consecutive statements.  The new rules will become effective during interim and annual periods beginning after December 15, 2011, with the exception of the requirement to present reclassification adjustments from other comprehensive income to net income on the face of the financial statements, which has been deferred pending further deliberation by the FASB.  Because the standard only impacts the presentation of comprehensive income and does not impact what is included in comprehensive income, the standard will not have a significant impact on the Company's consolidated financial statements. The Company adopted this accounting standard during the quarter ended March 31, 2012.

In September 2011, the FASB issued Accounting Standards Update No. 2011-08, “Intangibles – Goodwill and Other (Topic 350): Testing Goodwill for Impairment”("ASU"). This newly issued accounting standard is intended to reduce the cost and complexity of the annual goodwill impairment test by providing entities an option to perform a "qualitative" assessment to determine whether further impairment testing is necessary. Under the revised standard, an entity has the option to first assess qualitative factors to determine whether it is necessary to perform the current two-step impairment test. If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, the quantitative impairment test is required; otherwise, no further testing is required. Prior to the issuance of the revised standard, an entity was required to perform step one of the impairment test at least annually by calculating and comparing the fair value of a reporting unit to its carrying amount. Under the revised standard, if an entity determines that step one is necessary and the fair value of the reporting unit is less than its carrying amount, then step two of the test will continue to be required to measure the amount of the impairment loss, if any. These amendments do not change the current guidance for testing other indefinite-lived intangible assets for impairment. This ASU is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. The Company adopted this standard for the quarter ended June 30, 2012 and it did not impact the Company’s financial position or results from operations.

NOTE 2 – STOCK COMPENSATION

The following table represents total stock based compensation expense for non-qualified stock options, restricted stock units (“RSU”) and the tax related benefit for the three and six months ended June 30, 2012 and 2011:

 
Three Months Ended
 
Six Months Ended
(in thousands)
2012
 
2011
 
2012
 
2011
 
 
 
 
 
 
 
 
Stock option expense
$
3,298

 
$
3,035

 
$
5,679

 
$
5,373

RSU expense
3,094

 
2,296

 
4,640

 
4,347

Total stock based compensation expense
$
6,392

 
$
5,331

 
$
10,319

 
$
9,720

 
 
 
 
 
 
 
 
Total related tax benefit
$
1,916

 
$
1,620

 
$
2,935

 
$
2,872


At June 30, 2012, the remaining unamortized compensation cost related to non-qualified stock options is $19.1 million, which will be expensed over the weighted average remaining vesting period of the options, or 1.8 years. At June 30, 2012, the unamortized compensation cost related to RSU is $20.4 million, which will be expensed over the remaining restricted period of the RSU, or 1.7 years.


















9



The following table reflects the non-qualified stock option transactions from December 31, 2011 through June 30, 2012:
 
Outstanding
 
Exercisable
(in thousands, except per share data)
Shares
 
Weighted
Average
Exercise
Price
 
Aggregate
Intrinsic
Value
 
Shares
 
Weighted
Average
Exercise
Price
 
Aggregate
Intrinsic
Value
 
 
 
 
 
 
 
 
 
 
 
 
December 31, 2011
10,148

 
$
31.23

 
$
51,402

 
8,049

 
$
30.06

 
$
50,365

Granted
1,307

 
38.72

 
 

 
 

 
 

 
 

Exercised
(862
)
 
23.29

 
 

 
 

 
 

 
 

Cancelled
(25
)
 
41.15

 
 

 
 

 
 

 
 

Forfeited
(38
)
 
36.15

 
 

 
 

 
 

 
 

 
 
 
 
 
 
 
 
 
 
 
 
June 30, 2012
10,530

 
$
32.77

 
$
61,728

 
7,720

 
$
31.20

 
$
58,418


At June 30, 2012 the weighted average remaining contractual term of all outstanding options is 6.0 years and the weighted average remaining contractual term of exercisable options is 5.0 years.

The following table summarizes the unvested RSU transactions from December 31, 2011 through June 30, 2012:

(in thousands, except per share data)
Shares
 
Weighted Average
Grant Date
Fair Value
 
 
 
 
December 31, 2011
897

 
$
32.50

Granted
413

 
38.71

Vested
(244
)
 
26.28

Forfeited
(25
)
 
35.67

 
 
 
 
June 30, 2012
1,041

 
$
36.34


NOTE 3 – COMPREHENSIVE INCOME

During the quarter ended June 30, 2012, foreign currency translation adjustments included currency translation losses of $175.3 million and losses on the Company’s loans designated as hedges of net investments of $1.3 million.  During the quarter ended June 30, 2011, foreign currency translation adjustments included currency translation gains of $52.4 million and gains of $9.7 million on the Company’s loans designated as hedges of net investments.  During the six months ended June 30, 2012, foreign currency translation adjustments included currency losses of $48.5 million and gains on the Company's loans designated as hedges of net investments of $4.1 million. During the six months ended June 30, 2011, foreign currency translation adjustments included currency translation gains of $142.1 million and gains on the Company's loans designated as hedges as investments of $10.7 million. These foreign currency translation adjustments were offset by movements on derivative financial instruments, which are discussed in Note 10, Financial Instruments and Derivatives.

The balances included in AOCI, net of tax, in the consolidated balance sheets are as follows:

(in thousands)
June 30, 2012
 
December 31, 2011
 
 
 
 
Foreign currency translation adjustments
$
(83,489
)
 
$
(39,078
)
Net loss on derivative financial instruments
(102,433
)
 
(117,390
)
Net unrealized holding gains (losses) on available-for-sale securities
14,530

 
(516
)
Pension liability adjustments
(32,320
)
 
(33,986
)
 
$
(203,712
)
 
$
(190,970
)



10



The cumulative foreign currency translation adjustments included translation gains of $47.8 million and $96.3 million at June 30, 2012 and December 31, 2011, respectively, was more than offset by losses of $129.4 million and $133.5 million, respectively, on loans designated as hedges of net investments.  These foreign currency translation adjustments were partially offset by movements on derivatives financial instruments, which are discussed in Note 10, Financial Instruments and Derivatives.

NOTE 4 - EARNINGS PER COMMON SHARE

The dilutive effect of outstanding non-qualified stock options and RSU is reflected in diluted earnings per share by application of the treasury stock method. The following table sets forth the computation of basic and diluted earnings per common share for the three and six months ended June 30, 2012 and 2011:

 
Three Months Ended
 
Six Months Ended
Basic Earnings Per Common Share Computation
 
 
 
 
 
 
 
(in thousands, except per share amounts)
2012
 
2011
 
2012
 
2011
 
 
 
 
 
 
 
 
Net income attributable to DENTSPLY International
$
80,764

 
$
74,236

 
$
134,049

 
$
143,320

 
 
 
 
 
 
 
 
Common shares outstanding
141,737

 
141,052

 
141,729

 
141,331

 
 
 
 
 
 
 
 
Earnings per common share - basic
$
0.57

 
$
0.53

 
$
0.95

 
$
1.01

 
 
 
 
 
 
 
 
Diluted Earnings Per Common Share Computation
 

 
 

 
 

 
 

(in thousands, except per share amounts)
 

 
 

 
 

 
 

 
 
 
 
 
 
 
 
Net income attributable to DENTSPLY International
$
80,764

 
$
74,236

 
$
134,049

 
$
143,320

 
 
 
 
 
 
 
 
Common shares outstanding
141,737

 
141,052

 
141,729

 
141,331

Incremental shares from assumed exercise of dilutive options from stock-based compensation awards
2,126

 
2,321

 
2,179

 
2,363

Total shares
143,863

 
143,373

 
143,908

 
143,694

 
 
 
 
 
 
 
 
Earnings per common share - diluted
$
0.56

 
$
0.52

 
$
0.93

 
$
1.00


Options to purchase 3.8 million and 4.1 million shares of common stock that were outstanding during the three and six months ended June 30, 2012, respectively, were not included in the computation of diluted earnings per share since the exercise prices for these options were greater than the average market price of the common shares and, therefore, the effect would be antidilutive.  There were 3.0 million and 3.4 million antidilutive shares of common stock outstanding during the three and six months ended June 30, 2011, respectively.

NOTE 5 – BUSINESS ACQUISITIONS

On August 31, 2011, the Company acquired 100% of the outstanding common shares of Astra Tech, a leading developer, manufacturer and marketer of dental implants, customized implant abutments and consumable medical devices in the urology and surgery market segments.

The Astra Tech acquisition was recorded in accordance with the business combinations provisions of US GAAP.  The Company has preliminarily valued tangible and identifiable intangible assets acquired based on their estimated fair values.  The Company is in the process of completing the valuation of identifiable assets acquired and liabilities assumed and, therefore, the fair values set forth below are subject to adjustment upon finalizing the valuations. In addition, completion of the valuation may impact the assessment of the net deferred tax liability currently recognized with any adjustment resulting in a corresponding change to goodwill. The amount of these potential adjustments could be significant.

The following table summarizes the preliminary fair value of identifiable assets and liabilities assumed at the date of the Astra Tech acquisition. This table has been updated during the first six months of 2012 to reflect the refined estimates of fair value. The primary change resulted in an increase to identifiable intangible assets relating to customer relationships and a corresponding

11



reduction to goodwill.

(in thousands)
 
 
 
Inventory
$
84,659

Other Current assets
140,462

Property, plant and equipment
178,495

Identifiable intangible assets
986,300

Goodwill
824,357

Other long-term assets
13,438

Total assets
2,227,711

 
 
Current liabilities
106,983

Long-term liabilities
329,937

Total liabilities
436,920

 
 
Net assets
$
1,790,791


Other current assets consist primarily of trade accounts receivable of $101.2 million.  Current liabilities assumed are primarily comprised of accrued and other current liabilities of $80.0 million and trade accounts payable of $27.0 million.  Long-term liabilities assumed are primarily comprised of noncurrent deferred tax liabilities of $280.6 million and pension obligations of $49.3 million.

Inventory held by Astra Tech includes a fair value adjustment of $32.8 million.  The Company expensed this amount by December 31, 2011 as the acquired inventory was sold.

Property, plant and equipment includes a fair value adjustment of $28.7 million and consists of land, buildings, plant and equipment.  Depreciable lives range 40 years for buildings and from 5 to 15 years for plant and equipment.

The preliminary fair values assigned to identifiable intangible assets were determined through the use of the income approach, specifically the relief from royalty method and the multi-period excess earnings method. Both valuation methods rely on management’s judgments, including expected future cash flows resulting from existing customer relationships, customer attrition rates, contributory effects of other assets utilized in the business, peer group cost of capital and royalty rates as well as other factors. The valuation of tangible assets was derived using the combination of the income approach, the market approach and the cost approach. Significant judgments used in valuing tangible assets include estimated reproduction or replacement cost, useful lives of assets, estimated selling prices, costs to complete and reasonable profit.
       
Useful lives for identifiable intangible assets were determined based upon the remaining useful economic lives of the identifiable intangible assets that are expected to contribute to future cash flows.  The acquired identifiable intangible assets are being amortized on a straight-line basis over their expected useful lives.

Identifiable intangible assets acquired consist of the following:
(in thousands, except for useful life)
Amount
 
Useful Life
(in years)
 
 
 
 
Customer relationships
$
636,900

 
17.5 - 20
Developed technology and patents
116,500

 
10
Trade names and trademarks
229,100

 
Indefinite
In-process research and development
3,800

 
Total
$
986,300

 
 

The $824.4 million of goodwill is attributable to the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed. The goodwill recognized is primarily attributable to cost savings and other synergies that the Company expects to realize through operational efficiencies.  All of the goodwill has been assigned to the Company's Implants/Endodontics/Healthcare/Pacific Rim segment and is not expected to be deductible for tax purposes.

12




The following unaudited pro forma financial information reflects the consolidated results of operations of the Company had the Astra Tech acquisition occurred on January 1, 2010.  These amounts were calculated after conversion to US GAAP, applying the Company’s accounting policies and adjusting Astra Tech’s results to reflect the additional depreciation and amortization that would have been charged assuming the fair value adjustments to property, plant and equipment, inventory and intangible assets had been applied from January 1, 2010, together with the consequential tax effects at the statutory rate.  These adjustments also reflect the additional interest expense incurred on the debt to finance the acquisition.
 
Three Months Ended
June 30,
 
Six Months Ended June 30,
(in thousands, except per share data)
2011
 
2011
 
 
 
 
Net sales
$
763,659

 
$
1,479,567

Net income attributable to DENTSPLY
$
71,932

 
$
141,510

Diluted earnings per common share
$
0.50

 
$
0.98


The pro forma financial information is based on the Company's preliminary assignment of purchase price and therefore subject to adjustment upon finalizing the purchase price assignment. The Astra Tech financial information has been compiled in a manner consistent with the accounting policies adopted by DENTSPLY. Pro forma results do not include any anticipated synergies or other anticipated benefits of the acquisition. Accordingly, the unaudited pro forma financial information is not necessarily indicative of either future results of operations or results that might have been achieved had the acquisition occurred on January 1, 2010.  While the Company completed other transactions during the pro forma periods presented above, these transactions were immaterial to the Company’s net sales and net income attributable to DENTSPLY.

NOTE 6 - SEGMENT INFORMATION

The Company has numerous operating businesses covering a wide range of dental and certain healthcare products and geographic regions, primarily serving the professional dental market. Professional dental products represented approximately 89% and 97% of sales for the three months ended June 30, 2012 and 2011, respectively, and 89% and 97% of sales for the six months ended June 30, 2012 and 2011, respectively.

The operating businesses are combined into operating groups, which have overlapping product offerings, geographical presence, customer bases, distribution channels, and regulatory oversight. These operating groups are considered the Company’s reportable segments as the Company’s chief operating decision-maker regularly reviews financial results at the operating group level and uses this information to manage the Company’s operations. The accounting policies of the groups are consistent with those described in the Company’s most recently filed Form 10-K in the summary of significant accounting policies.  The Company measures segment income for reporting purposes as operating income before restructuring and other costs, interest expense, interest income, other income and expenses and income taxes.

During the first quarter of 2012 the Company realigned reporting responsibilities for multiple locations as a result of changes to the management structure. These changes also helped the Company gain operating efficiencies and effectiveness. The segment information below reflects the revised structure for all periods shown.

Dental Consumable and Laboratory Businesses

This business group includes responsibility for the design, manufacturing, sales and distribution of certain small equipment and chairside consumable products in the United States, Germany and certain other European regions.  It also has responsibility for the sales and distribution of certain Endodontic products in Germany. This business group also includes the responsibility for the design, manufacture, sales and distribution of most dental laboratory products, excluding certain countries. This business group is also responsible for most of the Company’s non-dental business excluding healthcare products.

Orthodontics/Canada/Mexico/Japan

  This business group is responsible for the world-wide manufacturing, sales and distribution of the Company’s Orthodontic products. It also has responsibility for the sales and distribution of most of the Company’s dental products sold in Japan, Canada and Mexico.



13




Select Distribution Businesses

This business group includes responsibility for the sales and distribution for most of the Company's dental products sold in France, United Kingdom, Italy, Austria and certain other European countries, Middle Eastern countries, India and Africa.

Implants/Endodontics/Healthcare/Pacific Rim

This business group includes the responsibility for the design, manufacture, sales and distribution of most of the Company’s dental implant and related products. This business group also includes the responsibility for the design and manufacturing of Endodontic products and is responsible for the sales and distribution of the Company’s Endodontic products in the United States, Switzerland, and locations not covered by other selling divisions.  In addition, this business group is also responsible for sales and distribution of certain Endodontic products in Germany, Asia and other parts of the world. Additionally, this business group is responsible for the design and manufacture of certain dental consumables and dental laboratory products and the sales and distribution of most dental products sold in Brazil, Latin America (excluding Mexico), Australia and most of Asia (excluding India and Japan). This business group is also responsible for the world-wide design, manufacturing, sales and distribution of the Company's healthcare products (non-dental) throughout most of the world.

Significant interdependencies exist among the Company’s operations in certain geographic areas. Inter-group sales are at prices intended to provide a reasonable profit to the manufacturing unit after recovery of all manufacturing costs and to provide a reasonable profit for purchasing locations after coverage of marketing and general and administrative costs.

Generally, the Company evaluates performance of the operating groups based on the groups’ operating income, excluding restructuring and other costs, and net third party sales, excluding precious metal content.

The following tables set forth information about the Company’s operating groups for the three and six months ended June 30, 2012 and 2011:

Third Party Net Sales
 
Three Months Ended
 
Six Months Ended
(in thousands)
2012
 
2011
 
2012
 
2011
 
 
 
 
 
 
 
 
Dental Consumable and Laboratory Businesses
$
258,786

 
$
246,062

 
$
505,717

 
$
477,182

Orthodontics/Canada/Mexico/Japan
86,317

 
85,728

 
159,219

 
174,174

Select Distribution Businesses
78,433

 
82,892

 
151,684

 
157,058

Implants/Endodontics/Healthcare/Pacific Rim
342,312

 
196,399

 
666,956

 
374,213

All Other (a)
(2,854
)
 
(1,638
)
 
(4,169
)
 
(2,681
)
Total
$
762,994

 
$
609,443

 
$
1,479,407

 
$
1,179,946

(a) Includes amounts recorded at Corporate headquarters.


















14




Third Party Net Sales, Excluding Precious Metal Content
 
Three Months Ended
 
Six Months Ended
(in thousands)
2012
 
2011
 
2012
 
2011
 
 
 
 
 
 
 
 
Dental Consumable and Laboratory Businesses
$
206,862

 
$
214,181

 
$
414,346

 
$
415,289

Orthodontics/Canada/Mexico/Japan
77,037

 
77,433

 
142,878

 
157,908

Select Distribution Businesses
77,130

 
80,490

 
148,783

 
152,530

Implants/Endodontics/Healthcare/Pacific Rim
340,305

 
193,523

 
662,268

 
367,949

All Other (a)
(2,854
)
 
(1,638
)
 
(4,169
)
 
(2,681
)
Total excluding precious metal content
698,480

 
563,989

 
1,364,106

 
1,090,995

Precious metal content
64,514

 
45,454

 
115,301

 
88,951

Total including precious metal content
$
762,994

 
$
609,443

 
$
1,479,407

 
$
1,179,946

(a) Includes amounts recorded at Corporate headquarters.

Inter-segment Net Sales
 
Three Months Ended
 
Six Months Ended
(in thousands)
2012
 
2011
 
2012
 
2011
 
 
 
 
 
 
 
 
Dental Consumable and Laboratory Businesses
$
58,486

 
$
55,636

 
$
112,887

 
$
111,006

Orthodontics/Canada/Mexico/Japan
1,054

 
953

 
2,233

 
1,937

Select Distribution Businesses
2,974

 
3,729

 
6,292

 
7,477

Implants/Endodontics/Healthcare/Pacific Rim
42,409

 
43,756

 
80,748

 
81,798

All Other (a)
56,329

 
55,458

 
110,309

 
106,835

Eliminations
(161,252
)
 
(159,532
)
 
(312,469
)
 
(309,053
)
Total
$

 
$

 
$

 
$

(a) Includes amounts recorded at Corporate headquarters and one distribution warehouse not managed by named segments.

Segment Operating Income
 
Three Months Ended
 
Six Months Ended
(in thousands)
2012
 
2011
 
2012
 
2011
 
 
 
 
 
 
 
 
Dental Consumable and Laboratory Businesses
$
63,295

 
$
61,536

 
$
124,764

 
$
117,519

Orthodontics/Canada/Mexico/Japan
3,897

 
4,314

 
4,263

 
13,593

Select Distribution Businesses
138

 
587

 
(850
)
 
445

Implants/Endodontics/Healthcare/Pacific Rim
77,224

 
63,188

 
143,383

 
117,613

All Other (a)
(33,119
)
 
(25,758
)
 
(71,729
)
 
(46,086
)
Segment operating income
111,435

 
103,867

 
199,831

 
203,084

 
 
 
 
 
 
 
 
Reconciling Items:
 

 
 

 
 

 
 

Restructuring and other costs
(2,528
)
 
(6,863
)
 
(3,765
)
 
(7,496
)
Interest expense
(14,584
)
 
(5,570
)
 
(30,366
)
 
(11,913
)
Interest income
2,011

 
2,430

 
4,308

 
4,258

Other expense (income), net
(748
)
 
(1,434
)
 
(1,230
)
 
(1,504
)
Income before income taxes
$
95,586

 
$
92,430

 
$
168,778

 
$
186,429

(a) Includes the results of Corporate headquarters, inter-segment eliminations and one distribution warehouse not managed by named segments.

15



Assets
 
 
 
(in thousands)
June 30, 2012
 
December 31, 2011
 
 
 
 
Dental Consumable and Laboratory Businesses
$
1,012,143

 
$
1,180,001

Orthodontics/Canada/Mexico/Japan
286,997

 
328,376

Select Distribution Businesses
207,377

 
168,500

Implants/Endodontics/Healthcare/Pacific Rim
3,102,736

 
2,881,591

All Other (a)
261,503

 
196,930

Total
$
4,870,756

 
$
4,755,398

(a) Includes the assets of Corporate headquarters, inter-segment eliminations and one distribution warehouse not managed by named segments.

NOTE 7 - INVENTORIES

Inventories are stated at the lower of cost or market.  At June 30, 2012 and December 31, 2011, the cost of $8.6 million, or 2.1% and $7.1 million, or 2.1% of inventories, respectively, was determined using the last-in, first-out (“LIFO”) method. The cost of the remaining inventories was determined using the first-in, first-out (“FIFO”) or average cost methods. If the FIFO method had been used to determine the cost of LIFO inventories, the amounts at which net inventories are stated would be higher than reported at June 30, 2012 and December 31, 2011 by $5.7 million and $5.6 million, respectively.

The Company establishes reserves for inventory in order to present the net realizable value.  The inventory valuation reserves were $34.9 million and $35.1 million at June 30, 2012 and December 31, 2011, respectively.

Inventories, net of inventory valuation reserves, consist of the following:
(in thousands)
June 30, 2012
 
December 31, 2011
 
 
 
 
Finished goods
$
246,432

 
$
218,814

Work-in-process
67,810

 
66,952

Raw materials and supplies
88,953

 
75,996

 
$
403,195

 
$
361,762


NOTE 8 - BENEFIT PLANS

The following sets forth the components of net periodic benefit cost of the Company’s defined benefit plans and for the Company’s other postretirement employee benefit plans for the three and six months ended June 30, 2012 and 2011:

Defined Benefit Plans 
Three Months Ended
 
Six Months Ended
(in thousands)
2012
 
2011
 
2012
 
2011
 
 
 
 
 
 
 
 
Service cost
$
3,032

 
$
2,578

 
$
6,010

 
$
5,012

Interest cost
2,627

 
2,305

 
5,318

 
4,492

Expected return on plan assets
(1,189
)
 
(1,290
)
 
(2,414
)
 
(2,506
)
Amortization of prior service cost
(33
)
 
21

 
(70
)
 
41

Amortization of net loss
494

 
405

 
992

 
788

 
 
 
 
 
 
 
 
Net periodic benefit cost
$
4,931

 
$
4,019

 
$
9,836

 
$
7,827



16



Other Postretirement Plans
Three Months Ended
 
Six Months Ended
(in thousands)
2012
 
2011
 
2012
 
2011
 
 
 
 
 
 
 
 
Service cost
$
18

 
$
16

 
$
37

 
$
32

Interest cost
118

 
139

 
235

 
277

Amortization of net loss
57

 
49

 
115

 
98

 
 
 
 
 
 
 
 
Net periodic benefit cost
$
193

 
$
204

 
$
387

 
$
407


The following sets forth the information related to the contributions to the Company’s benefit plans for 2012:
(in thousands)
Pension
Benefits
 
Other
Postretirement
Benefits
 
 
 
 
Actual contributions through June 30, 2012
$
6,386

 
$
416

Projected for the remainder of the year
6,095

 
562

Total for year
$
12,481

 
$
978



NOTE 9 – RESTRUCTURING AND OTHER COSTS

Restructuring Costs

During the three and six months ended June 30, 2012, the Company recorded restructuring costs of $2.1 million and $3.5 million, respectively.  These costs primarily related to employee severance.  During the three and six months ended June 30, 2011, the Company recorded restructuring costs of $0.7 million, related to employee severance costs.  These costs are recorded in “Restructuring and other costs” in the consolidated statements of operations and the associated liabilities are recorded in "Accrued liabilities" in the consolidated balance sheets.

During 2012, the Company initiated several restructuring plans primarily related to the integration, reorganization and closure or consolidation of certain production and selling facilities in order to better leverage the Company’s resources by minimizing costs and obtaining operational efficiencies.

At June 30, 2012, the Company’s restructuring accruals were as follows:
 
Severance
(in thousands)
2010 and
Prior Plans
 
2011 Plans
 
2012 Plans
 
Total
 
 
 
 
 
 
 
 
Balance at December 31, 2011
$
3,380

 
$
1,281

 
$

 
$
4,661

Provisions and adjustments

 
546

 
2,383

 
2,929

Amounts applied
(689
)
 
(452
)
 
(929
)
 
(2,070
)
Balance at June 30, 2012
$
2,691

 
$
1,375

 
$
1,454

 
$
5,520

 
 
Lease/Contract Terminations
(in thousands)
2010 and
Prior Plans
 
2012 Plans
 
Total
 
 
 
 
 
 
Balance at December 31, 2011
$
1,011

 
$

 
$
1,011

Provisions and adjustments

 
254

 
254

Amounts applied
(147
)
 
(27
)
 
(174
)
Balance at June 30, 2012
$
864

 
$
227

 
$
1,091



17



 
Other Restructuring Costs
(in thousands)
2010 and
Prior Plans
 
2012 Plans
 
Total
 
 
 
 
 
 
Balance at December 31, 2011
$
34

 
$

 
$
34

Provisions and adjustments

 
276

 
276

Amounts applied

 
(123
)
 
(123
)
Balance at June 30, 2012
$
34

 
$
153

 
$
187


The following table provides the year-to-date changes in the restructuring accruals by segment:
(in thousands)
December 31,
2011
 
Provisions and
Adjustments
 
Amounts
Applied
 
June 30, 2012
 
 
 
 
 
 
 
 
Dental Consumable and Laboratory Businesses
$
3,601

 
$
628

 
$
(1,006
)
 
$
3,223

Orthodontics/Canada/Mexico/Japan
240

 
826

 
(282
)
 
784

Implants/Endodontics/Healthcare/Pacific Rim
1,865

 
2,005

 
(1,079
)
 
2,791

 
$
5,706

 
$
3,459

 
$
(2,367
)
 
$
6,798


NOTE 10 – FINANCIAL INSTRUMENTS AND DERIVATIVES

Derivative Instruments and Hedging Activities

The Company's activities expose it to a variety of market risks, which primarily include the risks related to the effects of changes in foreign currency exchange rates, interest rates and commodity prices. These financial exposures are monitored and managed by the Company as part of its overall risk management program. The objective of this risk management program is to reduce the volatility that these market risks may have on the Company's operating results and equity. The Company employs derivative financial instruments to hedge certain anticipated transactions, firm commitments, or assets and liabilities denominated in foreign currencies. Additionally, the Company utilizes interest rate swaps to convert variable rate debt to fixed rate debt and to convert fixed rate debt to variable rate debt, cross currency basis swaps to convert debt denominated in one currency to another currency and commodity swaps to fix certain variable raw material costs.

Derivative instruments not designated as hedging

The Company enters into derivative financial instruments to hedge the foreign exchange revaluation risk associated with recorded assets and liabilities that are denominated in a non-functional currency. The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying non-functional currency balances and are recorded in “Other expense (income), net” on the consolidated statements of operations. The Company primarily uses forward foreign exchange contracts and cross currency basis swaps to hedge these risks. The Company's significant contracts outstanding as of June 30, 2012 are summarized in the tables that follow.
 
The Company wrote DIO equity option contracts ("equity options") to the original sellers of the DIO investment for the remaining DIO common shares held by the sellers. The equity options provide the sellers the ability to require the Company to purchase their remaining shares on hand at a price based on an agreed-upon formula at specific time frames in the future. The sellers are also allowed to sell their remaining shares on the open market. Changes in the fair value of the equity options are reported in “Other expense (income), net” on the consolidated statements of operations. This derivative is further discussed in Note 11, Fair Value Measurement.

Cash Flow Hedges

Foreign Exchange Risk Management
 
The Company uses a layered hedging program to hedge select anticipated foreign currency cash flows to reduce volatility in both cash flows and reported earnings of the consolidated Company. The Company accounts for the foreign exchange forward contracts as cash flow hedges. As a result, the Company records the fair value of the contract primarily through AOCI based on the tested effectiveness of the foreign exchange forward contracts. The Company measures the effectiveness of cash flow hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be deferred in AOCI and released and recorded on the consolidated statements of operations in the

18



same period that the hedged transaction is recorded. Any time value component of the hedge fair value is deemed ineffective and will be reported currently in “Other expense (income), net” on the consolidated statements of operations in the period which it is applicable. Any cash flows associated with these instruments are included in cash from operations in accordance with the Company's policy of classifying the cash flows from these instruments in the same category as the cash flows from the items being hedged.
 
These foreign exchange forward contracts generally have maturities up to eighteen months and the counterparties to the transactions are typically large international financial institutions. The Company's significant contracts outstanding as of June 30, 2012 are summarized in the tables that follow.

Interest Rate Risk Management
 
The Company uses interest rate swaps to convert a portion of its variable interest rate debt to fixed interest rate debt. As of June 30, 2012, the Company has two groups of significant interest rate swaps. One of the groups of swaps has notional amounts totaling 12.6 billion Japanese yen, and effectively converts the underlying variable interest rates to an average fixed interest rate of 0.2% for a term of three years, ending in September 2014. Another swap has a notional amount of 65.0 million Swiss francs, and effectively converts the underlying variable interest rates to a fixed interest rate of 0.7% for a term of five years, ending in September 2016.
The Company enters into interest rate swap contracts infrequently as they are only used to manage interest rate risk on long-term debt instruments and not for speculative purposes. The Company's significant contracts outstanding as of June 30, 2012 are summarized in the tables that follow.
Commodity Risk Management
 
The Company selectively enters into commodity swaps to effectively fix certain variable raw material costs. These swaps are used purely to stabilize the cost of components used in the production of certain of the Company's products. The Company generally accounts for the commodity swaps as cash flow hedges. As a result, the Company records the fair value of the swap primarily through AOCI based on the tested effectiveness of the commodity swap. The Company measures the effectiveness of cash flow hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be deferred in AOCI and released and recorded on the consolidated statements of operations in the same period that the hedged transaction is recorded. At any time the value component of the hedge fair value is deemed ineffective and will be reported currently in “Interest expense” in the period which it is applicable. Any cash flows associated with these instruments are included in cash from operations in accordance with the Company's policy of classifying the cash flows from these instruments in the same category as the cash flows from the items being hedged.
At June 30, 2012, the Company had swaps in place to purchase 766 troy ounces of platinum bullion for use in production at an average fixed rate of $1,467 per troy ounce.  In addition, the Company had swaps in place to purchase 76,870 troy ounces of silver bullion for use in production at an average fixed rate of $28 per troy ounce.
 





















19



The following tables summarize the notional amounts and fair value of the Company's cash flow hedges and non-designated derivatives at June 30, 2012:
Foreign Exchange Forward Contracts
 
Notional Amounts Maturing in the Year
 
Fair Value Net
Asset (Liability)
(in thousands)  
 
2012
 
2013
 
2014
 
June 30, 2012
 
 
 
 
 
 
 
 
 
Forward sale, 12.3 million Australian dollars
 
$
8,061

 
$
3,884

 
$
139

 
$
(698
)
Forward purchase, 7.4 million British pounds
 
(11,326
)
 
(193
)
 

 
167

Forward sale, 43.6 million Canadian dollars
 
21,955

 
20,015

 
1,212

 
862

Forward purchase, 22.2 million Danish kroner
 
(3,773
)
 

 

 
(24
)
Forward sale, 143.4 million euros
 
63,919

 
112,840

 
5,835

 
4,080

Forward purchase, 0.4 billion Japanese yen
 
4,471

 
(8,569
)
 
(506
)
 
(343
)
Forward sale, 165.2 million Mexican pesos
 
12,384

 

 

 
(502
)
Forward purchase, 17.2 million Norwegian kroner
 
(2,893
)
 

 

 
14

Forward sale, 4.2 million Polish zlotys
 
1,259

 

 

 
(49
)
Forward sale, 2.6 million Singapore dollars
 
2,065

 

 

 
20

Forward sale, 5.7 billion South Korean won
 
4,994

 

 

 
(35
)
Forward purchase, 1.0 billion Swedish kronor
 
(69,982
)
 
(67,198
)
 
(3,270
)
 
3,080

Forward purchase, 14.0 million Swiss francs
 
(33,566
)
 
19,233

 
860

 
1,229

Forward sale, 32.5 million Taiwanese dollars
 
1,092

 

 

 
(4
)
Total foreign exchange forward contracts
 
$
(1,340
)
 
$
80,012

 
$
4,270

 
$
7,797


Interest Rate Swaps
 
Notional Amounts Maturing in the Year
 
Fair Value Net
Asset (Liability)
(in thousands)
 
2012
 
2013
 
2014
 
2015
 
2016 and Beyond
 
June 30, 2012
 
 
 
 
 
 
 
 
 
 
 
 
 
Euro
 
$
598

 
$
1,195

 
$
914

 
$
914

 
$
2,057

 
$
(550
)
Japanese yen
 

 

 
157,053

 

 

 
376

Swiss francs
 

 

 

 

 
68,482

 
(1,315
)
Total interest rate swaps
 
$
598

 
$
1,195

 
$
157,967

 
$
914

 
$
70,539

 
$
(1,489
)

Commodity Swap Contracts
 
Notional Amounts Maturing
in the Year
 
Fair Value Net 
Asset (Liability)
(in thousands)
 
2012
 
2013
 
June 30, 2012
 
 
 
 
 
 
 
Silver swap - U.S. dollar
 
$
1,526

 
$
563

 
$
(84
)
Platinum swap - U.S. dollar
 
777

 
321

 
(25
)
Total commodity swap contracts
 
$
2,303

 
$
884

 
$
(109
)

Cross Currency Basis Swap
 
Notional Amounts
Maturing in the Year
 
Fair Value Net
Asset (Liability)
(in thousands)
 
2014
 
June 30, 2012
 
 
 
 
 
Euro 449.8 million @ $1.45  pay USD 3 mth. LIBOR receive EUR 3 mth. EURIBOR
 
$
569,267

 
$
(79,689
)
Total cross currency basis swap
 
$
569,267

 
$
(79,689
)

20




At June 30, 2012, deferred net gains on derivative instruments of $3.7 million, which were recorded in AOCI, are expected to be reclassified to current earnings during the next twelve months. This reclassification is primarily due to the sale of inventory that includes previously hedged purchases and interest rate swaps. The maximum term over which the Company is hedging exposures to variability of cash flows (for all forecasted transactions, excluding interest payments on variable interest rate debt) is eighteen months. Overall, the derivatives designated as cash flow hedges are highly effective. Any cash flows associated with these instruments are included in cash from operations in accordance with the Company's policy of classifying the cash flows from these instruments in the same category as the cash flows from the items being hedged.

Hedges of Net Investments in Foreign Operations

The Company has numerous investments in foreign subsidiaries. The net assets of these subsidiaries are exposed to volatility in currency exchange rates. Currently, the Company uses both non-derivative financial instruments, including foreign currency denominated debt held at the parent company level and derivative financial instruments to hedge some of this exposure. Translation gains and losses related to the net assets of the foreign subsidiaries are offset by gains and losses in the non-derivative and derivative financial instruments designated as hedges of net investments, which are included in AOCI.

During the second quarter of 2012, the Company entered into two new cross currency basis swaps totaling Swiss francs 56.6 million (the “Swiss Swaps”). The Swiss Swaps mature in May 2015, and the Company pays three-month Swiss franc London Inter-Bank Offered Rate ("LIBOR") minus 37.9 basis points on Swiss francs 56.6 million and receives three-month U.S. dollar LIBOR on $60.5 million. The new contracts were entered into to replace maturing contracts. The Swiss Swaps are designated as net investment hedges of the Swiss denominated net assets. The interest rate differential is recognized in the earnings as interest income or interest expense as it is accrued. The foreign currency revaluation is recorded in AOCI, net of tax effects.
 
At June 30, 2012 and December 31, 2011, the Company had Swiss franc-denominated and Japanese yen-denominated debt and cross currency basis swaps denominated in euro and Swiss franc to hedge the currency exposure related to a designated portion of the net assets of its European, Swiss and Japanese subsidiaries. The fair value of the cross currency interest rate swap agreements is the estimated amount the Company would (pay) receive at the reporting date, taking into account the effective interest rates and foreign exchange rates. At June 30, 2012 and December 31, 2011, the estimated net fair values of the cross currency interest rate swap agreements was a liability of $74.5 million and a liability of $111.9 million, respectively, which are recorded in AOCI, net of tax effects. At June 30, 2012 and December 31, 2011, the accumulated translation gain (loss) on investments in foreign subsidiaries, primarily denominated in euros, Swiss francs, Japanese yen and Swedish krona, net of these net investment hedges, were $173.8 million in losses and $143.7 million in losses, respectively, which were included in AOCI, net of tax effects.

The following tables summarize the notional amounts and fair value of the Company's cross currency basis swaps that are designated as hedges of net investments in foreign operations at June 30, 2012:
Cross Currency Basis Swaps
Notional Amounts Maturing in the Year
 
Fair Value Net
Asset (Liability)
(in thousands)
 
2013
 
2014
 
2015
 
June 30, 2012

 
 
 
 
 
 
 
 
 
Swiss franc 592.5 million @ 1.09 pay CHF 3 mth. LIBOR rec. USD 3 mth. LIBOR
 
$
479,903

 
$
84,707

 
$
59,632

 
$
(79,240
)
Euro 618.0 million @ $1.27 pay EUR 3 mth. EURIBOR rec. USD 3 mth. LIBOR
 
782,203

 

 

 
4,700

Total cross currency basis swaps
 
$
1,262,106

 
$
84,707

 
$
59,632

 
$
(74,540
)

Fair Value Hedges
 
Effective April 4, 2011, the Company entered into a group of U.S. dollar denominated interest rate swaps with an initial total notional value of $150.0 million to effectively convert the underlying fixed interest rate of 4.1% on the Company's $250.0 million Private Placement Notes ("PPN") to variable rate for a term of five years, ending February 2016. The notional value of the swaps will decline proportionately as portions of the PPN mature. These interest rate swaps are designated as fair value hedges of the interest rate risk associated with the hedged portion of the fixed rate PPN. Accordingly, the Company will carry the portion of the hedged debt at fair value, with the change in debt and swap offsetting each other in the income statement. At June 30, 2012, the estimated net fair value of these interest rate swaps was $4.8 million.



21




 

The following tables summarize the notional amounts and fair value of the Company's fair value hedges at June 30, 2012:
Interest Rate Swap
 
Notional Amounts Maturing in the Year
 
Fair Value Net
Asset (Liability)
(in thousands)
 
2014
 
2015
 
2016 and Beyond
 
June 30, 2012
 
 
 
 
 
 
 
 
 
U.S. dollars
 
$
45,000

 
$
60,000

 
$
45,000

 
$
4,832

Total interest rate swap
 
$
45,000

 
$
60,000

 
$
45,000

 
$
4,832


The following tables summarize the fair value and consolidated balance sheet location of the Company's derivatives at June 30, 2012 and December 31, 2011:
 
 
June 30, 2012
(in thousands)
 
Prepaid
Expenses
and Other
Current Assets
 
Other
Noncurrent
Assets, Net
 
Accrued
Liabilities
 
Other
Noncurrent
Liabilities
Designated as Hedges
 
 
 
 
 
 
 
 
 
 
 
 
 
Foreign exchange forward contracts
 
$
6,143

 
$
754

 
$
883

 
$
123

Commodity contracts
 

 

 
109

 

Interest rate swaps
 
2,505

 
3,156

 

 
1,768

Cross currency basis swaps
 

 
31,494

 
82,949

 
23,085

Total
 
$
8,648

 
$
35,404

 
$
83,941

 
$
24,976

Not Designated as Hedges
 
 

 
 

 
 

 
 

 
 
 
 
 
 
 
 
 
Foreign exchange forward contracts
 
$
3,672

 
$

 
$
1,766

 
$

DIO equity option contracts
 

 

 

 
580

Interest rate swaps
 

 

 
108

 
442

Cross currency basis swaps
 

 

 

 
79,689

Total
 
$
3,672

 
$

 
$
1,874

 
$
80,711


 
 
December 31, 2011
(in thousands)
 
Prepaid
Expenses
and Other
Current Assets
 
Other
Noncurrent
Assets, Net
 
Accrued
Liabilities
 
Other
Noncurrent
Liabilities
Designated as Hedges
 
 
 
 
 
 
 
 
 
 
 
 
 
Foreign exchange forward contracts
 
$
5,464

 
$
896

 
$
641

 
$
107

Commodity contracts
 

 
15

 
257

 
2

Interest rate swaps
 
2,539

 
3,160

 

 
1,050

Cross currency basis swaps
 

 
19,838

 
13,790

 
117,974

Total
 
$
8,003

 
$
23,909

 
$
14,688

 
$
119,133

Not Designated as Hedges
 
 

 
 

 
 

 
 

 
 
 
 
 
 
 
 
 
Foreign exchange forward contracts
 
$
1,943

 
$

 
$
3,150

 
$

Commodity contracts
 

 

 

 
419

Interest rate swaps
 

 

 
105

 
476

Cross currency basis swaps
 

 

 

 
67,690

Total
 
$
1,943

 
$

 
$
3,255

 
$
68,585





22






The following tables summarize the statements of operations impact of the Company's cash flow hedges for the three and six months ended June 30, 2012 and 2011:

Three Months Ended June 30, 2012
 
 
 
 
 
 
Derivatives in Cash Flow Hedging
 
 
 
 
 
 
(in thousands)
 
Gain (Loss)
in AOCI
 
Classification
of Gains (Losses)
 
Effective Portion
Reclassified from
AOCI into Income
 
 
 
 
 
 
 
Interest rate contracts
 
$
(727
)
 
Interest expense
 
$
(897
)
Foreign exchange forward contracts
 
4,785

 
Cost of products sold
 
1,842

Foreign exchange forward contracts
 
391

 
SG&A expenses
 
226

Commodity contracts
 
(581
)
 
Cost of products sold
 
96

Total
 
$
3,868

 
 
 
$
1,267


Derivatives in Cash Flow Hedging
 
 
 
 
 
 
Classification
of Gains (Losses)
 
Ineffective portion
Recognized
in Income
(in thousands)
 
 
 
 
 
 
Foreign exchange forward contracts
 
Other expense, net
 
$
278

Commodity contracts
 
Interest expense
 
11

Total
 
 
 
$
289

 
Three Months Ended June 30, 2011
 
 
 
 
 
 
Derivatives in Cash Flow Hedging
 
 
 
 
 
 
(in thousands)
 
Gain (Loss)
in AOCI
 
Classification
of Gains (Losses)
 
Effective Portion
Reclassified from
AOCI into Income
 
 
 
 
 
 
 
Interest rate swaps
 
$
9,879

 
Interest expense
 
$
(1,318
)
Foreign exchange forward contracts
 
238

 
Cost of products sold
 
386

Foreign exchange forward contracts
 
(195
)
 
SG&A expenses
 
(95
)
Commodity contracts
 
29

 
Cost of products sold
 
91

Total
 
$
9,951

 
 
 
$
(936
)
Derivatives in Cash Flow Hedging
 
 
 
 
(in thousands)
 
Classification
of Gains (Losses)
 
Ineffective Portion
Recognized
in Income
 
Interest rate swaps
 
Other expense, net
 
$
65

Foreign exchange forward contracts
 
Interest expense
 
(188
)
Commodity contracts
 
Interest expense
 
1

Total
 
 
 
$
(122
)


23



Six Months Ended June 30, 2012
 
 
 
 
 
 
Derivatives in Cash Flow Hedging
 
 
 
 
 
 
(in thousands)
 
Gain (Loss)
in AOCI
 
Classification
of Gains (Losses)
 
Effective Portion
Reclassified from
AOCI into Income
 
 
 
 
 
 
 
Interest rate swaps
 
$
(1,399
)
 
Interest expense
 
$
(1,802
)
Foreign exchange forward contracts
 
3,351

 
Cost of products sold
 
2,992

Foreign exchange forward contracts
 
302

 
SG&A expenses
 
457

Commodity contracts
 
257

 
Cost of products sold
 
50

Total
 
$
2,511

 
 
 
$
1,697

Derivatives in Cash Flow Hedging
 
 
 
 
(in thousands)
 
Classification of Gains (Losses)
 
Ineffective Portion Recognized in Income
 
 
 
 
 
Foreign exchange forward contracts
 
Interest expense
 
$
478

Commodity contracts
 
Interest expense
 
(6
)
Total
 
 
 
$
472


Six Months Ended June 30, 2011
 
 
 
 
 
 
Derivatives in Cash Flow Hedging
 
 
 
 
 
 
(in thousands)
 
Gain (Loss)
in AOCI
 
Classification
of Gains (Losses)
 
Effective Portion
Reclassified from
AOCI into Income
 
 
 
 
 
 
 
Interest rate swaps
 
$
9,598

 
Interest expense
 
$
(2,569
)
Foreign exchange forward contracts
 
(694
)
 
Cost of products sold
 
854

Foreign exchange forward contracts
 
(462
)
 
SG&A expenses
 
11

Commodity contracts
 
56

 
Cost of products sold
 
196

Total
 
$
8,498

 
 
 
$
(1,508
)

Derivatives in Cash Flow Hedging
 
 
 
 
(in thousands)
 
Classification of Gains (Losses)
 
Ineffective Portion Recognized in Income
 
 
 
 
 
Interest rate swaps
 
Other expense, net
 
$
167

Foreign exchange forward contracts
 
Interest expense
 
(216
)
Foreign exchange forward contracts
 
Other expense, net
 
(188
)
Commodity contracts
 
Interest expense
 
(2
)
Total
 
 
 
$
(239
)













24



The following tables summarize the statements of operations impact of the Company's hedges of net investments for the three and six months ended June 30, 2012 and 2011:

Three Months Ended June 30, 2012
Derivatives in Net Investment Hedging
 
 
 
 
 
 
(in thousands)
 
Gain (Loss)
in AOCI
 
Classification
of Gains (Losses)
 
Gain (Loss)
Recognized
in Income
 
 
 
 
 
 
 
Cross currency interest rate swaps
 
$
73,784

 
Interest income
 
$
861

 
 
 
 
Interest expense
 
(412
)
Total
 
$
73,784

 
 
 
$
449


Three Months Ended June 30, 2011
Derivatives in Net Investment Hedging
 
 
 
 
 
 
(in thousands)
 
Gain (Loss)
in AOCI
 
Classification
of Gains (Losses)
 
Gain (Loss)
Recognized
in Income
 
 
 
 
 
 
 
Cross currency interest rate swaps
 
$
(70,023
)
 
Interest income
 
$
170

 
 
 
 
Interest expense
 
(1,310
)
Total
 
$
(70,023
)
 
 
 
$
(1,140
)
Six Months Ended June 30, 2012
Derivatives in Net Investment Hedging
 
 
 
 
 
 
(in thousands)
 
Gain (Loss)
in AOCI
 
Classification
of Gains (Losses)
 
Gain (Loss)
Recognized
in Income
 
 
 
 
 
 
 
Cross currency interest rate swaps
 
$
23,415

 
Interest income
 
$
1,633

 
 
 
 
Interest expense
 
(1,618
)
Total
 
$
23,415

 
 
 
$
15


Six Months Ended June 30, 2011
Derivatives in Net Investment Hedging
 
 
 
 
 
 
(in thousands)
 
Gain (Loss)
in AOCI
 
Classification
of Gains (Losses)
 
Gain (Loss)
Recognized
in Income
 
 
 
 
 
 
 
Cross currency interest rate swaps
 
$
(112,703
)
 
Interest income
 
$
369

 
 
 
 
Interest expense
 
(2,291
)
Total
 
$
(112,703
)
 
 
 
$
(1,922
)

The following tables summarize the statements of operations impact of the Company's hedges of fair value for the three and six months ended June 30, 2012 and 2011:

Derivatives in Fair Value Hedging
 
 
 
 
 
 
 
 
Classification
 
Three Months Ended June 30,
(in thousands)
 
of Gains (Losses)
 
2012
 
2011
 
 
 
 
 
 
 
Interest rate contracts
 
Interest expense
 
$
646

 
$
615

Total
 
 
 
$
646

 
$
615


25



Derivatives in Fair Value Hedging
 
 
 
 
 
 
 
 
Classification
 
Six Months Ended June 30,
(in thousands)
 
of Gains (Losses)
 
2012
 
2011
 
 
 
 
 
 
 
Interest rate contracts
 
Interest expense
 
$
1,485

 
$
615

Total
 
 
 
$
1,485

 
$
615


The following table summarizes the statements of operations impact of the Company's hedges not designated as hedging for the three and six months ended June 30, 2012 and 2011:

Derivatives Not Designated as Hedging
 
 
Classification
 
Three Months Ended June 30,
(in thousands)
 
of Gains (Losses)
 
2012
 
2011
 
 
 
 
 
 
 
Foreign exchange forward contracts
 
Other expense, net
 
$
(2,545
)
 
$
(394
)
DIO equity option contracts
 
Other expense, net
 
95

 
26

Interest rate contracts
 
Interest expense
 
(45
)
 
107

Cross currency interest rate contracts (a)
 
Other expense, net
 
(30,427
)
 

Cross currency interest rate contracts
 
Interest expense
 
(261
)
 

Cross currency interest rate contracts
 
Interest income
 
27

 

Total
 
 
 
$
(33,156
)
 
$
(261
)

Derivatives Not Designated as Hedging
 
 
Classification
 
Six Months Ended June 30,
(in thousands)
 
of Gains (Losses)
 
2012
 
2011
 
 
 
 
 
 
 
Foreign exchange forward contracts
 
Other expense, net
 
$
306

 
$
1,309

DIO equity option contracts
 
Other expense, net
 
(178
)
 
26

Interest rate contracts
 
Interest expense
 
(87
)
 
51

Cross currency interest rate contracts (a)
 
Other expense, net
 
(12,301
)
 

Cross currency interest rate contracts
 
Interest expense
 
(261
)
 

Cross currency interest rate contracts
 
Interest income
 
446

 

Total
 
 
 
$
(12,075
)
 
$
1,386


(a) The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying intercompany loans which are recorded in “Other expense (income), net” on the consolidated statements of operations.
















26



Amounts recorded in AOCI related to cash flow hedging instruments at:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
(in thousands, net of tax)
 
2012
 
2011
 
2012
 
2011
 
 
 
 
 
 
 
 
 
Beginning balance
 
$
(13,944
)
 
$
(2,275
)
 
$
(12,737
)
 
$
(1,468
)
 
 
 
 
 
 
 
 
 
Changes in fair value of derivatives
 
3,054

 
6,137

 
2,277

 
5,101

Reclassifications to earnings from equity
 
(1,267
)
 
467

 
(1,697
)
 
696

Total activity
 
1,787

 
6,604

 
580

 
5,797

 
 
 
 
 
 
 
 
 
Ending balance
 
$
(12,157
)
 
$
4,329

 
$
(12,157
)
 
$
4,329


Amounts recorded in AOCI related to hedges of net investments in foreign operations at:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
(in thousands, net of tax)
 
2012
 
2011
 
2012
 
2011
 
 
 
 
 
 
 
 
 
Beginning balance
 
$
(42,524
)
 
$
106,664

 
$
(143,730
)
 
$
45,417

 
 
 
 
 
 
 
 
 
Foreign currency translation adjustment
 
(175,281
)
 
66,059

 
(48,473
)
 
152,497

Changes in fair value of:
 
 
 
 
 
 
 
 
Foreign currency debt
 
(1,262
)
 
(6,687
)
 
4,062

 
(5,673
)
Derivative hedge instruments
 
45,303

 
(42,995
)
 
14,377

 
(69,200
)
Total activity
 
(131,240
)
 
16,377

 
(30,034
)
 
77,624

 
 
 
 
 
 
 
 
 
Ending balance
 
$
(173,764
)
 
$
123,041

 
$
(173,764
)
 
$
123,041


NOTE 11 – FAIR VALUE MEASUREMENT

The Company records financial instruments at fair value with unrealized gains and losses related to certain financial instruments reflected in AOCI on the consolidated balance sheets.  In addition, the Company recognizes certain liabilities at fair value.  The Company applies the market approach for recurring fair value measurements.  Accordingly, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs.

The fair value of financial instruments is determined by reference to various market data and other valuation techniques as appropriate. The Company believes the carrying amounts of cash and cash equivalents, accounts receivable (net of allowance for doubtful accounts), prepaid expenses and other current assets, accounts payable, accrued liabilities, income taxes payable and notes payable approximate fair value due to the short-term nature of these instruments.  The Company estimated the fair value and carrying value of total long-term debt, including the current portion, was $1,524.4 million and $1,483.9 million, respectively, at June 30, 2012.   At December 31, 2011, the Company estimated the fair value and carrying value, including the current portion, was $1,512.5 million and $1,491.4 million respectively.  The interest rate on the $450.0 million Senior Notes, the $300.0 million Senior Notes, and the $250.0 million PPN are fixed rates of 4.1%, 2.8% and 4.1%, respectively, and their fair value is based on the interest rates as of June 30, 2012. The interest rates on variable rate term loan debt and commercial paper are consistent with current market conditions, therefore the fair value of these instruments approximates their carrying values.

The following tables set forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis at June 30, 2012 and December 31, 2011, which are classified as “Cash and cash equivalents,” “Prepaid expenses and other current assets,” “Other noncurrent assets, net,” “Accrued liabilities,” and “Other noncurrent liabilities” on the consolidated balance sheets.  Financial assets and liabilities that are recorded at fair value as of the balance sheet date are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.


27



 
June 30, 2012
(in thousands)
Total
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
Assets
 
 
 
 
 
 
 
Interest rate swaps
$
5,661

 
$

 
$
5,661

 
$

Cross currency interest rate swaps
31,494

 

 
31,494

 

Foreign exchange forward contracts
10,569

 

 
10,569

 

Corporate convertible bonds
68,396

 

 

 
68,396

Total assets
$
116,120

 
$

 
$
47,724

 
$
68,396

 
 
 
 
 
 
 
 
Liabilities
 

 
 

 
 

 
 

Interest rate swaps
$
2,318

 
$

 
$
2,318

 
$

Commodity forward purchase contracts
109

 

 
109

 

Cross currency interest rate swaps
185,723

 

 
185,723

 

Foreign exchange forward contracts
2,772

 

 
2,772

 

Long term debt
154,895

 

 
154,895

 

Contingent considerations on acquisitions
823

 

 

 
823

DIO equity option contracts
580

 

 

 
580

Total liabilities
$
347,220

 
$

 
$
345,817

 
$
1,403


 
December 31, 2011
(in thousands)
Total
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
Assets
 
 
 
 
 
 
 
Money market funds
$
10,516

 
$
10,516

 
$

 
$

Interest rate swaps
5,699

 

 
5,699

 

Commodity forward purchase contracts
15

 

 
15

 

Cross currency interest rate swaps
19,838

 

 
19,838

 

Foreign exchange forward contracts
8,303

 

 
8,303

 

Corporate convertible bonds
47,850

 

 

 
47,850

Total assets
$
92,221

 
$
10,516

 
$
33,855

 
$
47,850

 
 
 
 
 
 
 
 
Liabilities
 

 
 

 
 

 
 

Interest rate swaps
$
1,631

 
$

 
$
1,631

 
$

Commodity forward purchase contracts
259

 

 
259

 

Cross currency interest rate swaps
199,454

 

 
199,454

 

Foreign exchange forward contracts
3,898

 

 
3,898

 

Long term debt
154,512

 

 
154,512

 

Contingent considerations on acquisitions
2,917

 

 

 
2,917

DIO equity option contracts
419

 

 

 
419

Total liabilities
$
363,090

 
$

 
$
359,754

 
$
3,336


Derivative valuations are based on observable inputs to the valuation model including interest rates, foreign currency exchange rates, future commodities prices and credit risks.  The commodity contracts, certain interest rate swaps and foreign exchange forward contracts are considered cash flow hedges and certain cross currency interest rate swaps are considered hedges of net investments in foreign operations as discussed in Note 10, Financial Instruments and Derivatives.

The Company uses the income method valuation technique to estimate the fair value of the corporate bonds.  The significant unobservable inputs for valuing the corporate bonds are DIO Corporation’s stock volatility factor of approximately 40% and corporate bond rating which implies an approximately 15% discount rate on the valuation model.  Significant observable inputs used to value the corporate bonds include foreign exchange rates and DIO Corporation’s period-ending market stock price.


28



The Company has valued the DIO equity option contracts using a Monte Carlo simulation which uses several estimates and probability assumptions by management including the future stock price, the stock price as a multiple of DIO earnings and the probability of the sellers to reduce their shares held by selling into the open market.  The fair value of equity option contracts are reported in “Other noncurrent liabilities,” on the consolidated balance sheets and changes in the fair value are reported in “Other expense (income), net” on the consolidated statements of operations.

Certain purchase agreements for acquisitions completed after January 1, 2009 contain provisions where the seller could receive additional consideration based on the future operating performance of the acquired business.  In accordance with US GAAP, the Company has recorded the fair value of these additional payments on the acquisition date. The fair value was based on a probability-weighted average payout discounted using a market rate of approximately 5%.  The fair value is subject to management’s estimates at the time of the acquisition and is based upon level 3 inputs.  The fair values of these additional payments are reported in “Other noncurrent liabilities,” on the consolidated balance sheets. 

The following table presents a reconciliation of the Company’s level 3 holdings measured at fair value on a recurring basis using unobservable inputs:
(in thousands)
Corporate
Convertible
Bonds
 
DIO Equity
Options
Contracts
 
Contingent
Considerations
 
 
 
 
 
 
Balance at December 31, 2011
$
47,850

 
$
(424
)
 
$
2,917

Payments, gross

 

 
(1,781
)
Adjustments:
 
 
 
 
 
     Reported in selling, general and administrative expense

 

 
(326
)
Unrealized gain:
 

 
 

 
 

Reported in AOCI
22,023

 

 

Unrealized loss:
 

 
 

 
 

Reported in other expense (income), net

 
(178
)
 

Effects of exchange rate changes
(1,477
)
 
14

 
13

Balance at June 30, 2012
$
68,396

 
$
(588
)
 
$
823


For the six months ended June 30, 2012, there were no purchases, issuances or transfers of level 3 financial instruments. The Company paid $1.8 million of contingent considerations.

NOTE 12 – INCOME TAXES

Uncertainties in Income Taxes

The Company recognizes in the consolidated financial statements, the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position.

It is reasonably possible that certain amounts of unrecognized tax benefits will significantly increase or decrease within twelve months of the reporting date of the Company’s consolidated financial statements. Final settlement and resolution of outstanding tax matters in various jurisdictions during the next twelve months could include unrecognized tax benefits of approximately $1.3 million.  In addition, expiration of statutes of limitation in various jurisdictions during the next twelve months could include unrecognized tax benefits of approximately $0.3 million.

NOTE 13 - FINANCING ARRANGEMENTS

The Company estimated the fair value and carrying value of its total long-term debt, including the current portion, was $1,512.8 million and $1,482.6 million, respectively, at June 30, 2012. At December 31, 2011, the fair value and the carrying value of its total long-term debt, including the current portion, were $1,512.5 million and $1,491.4 million, respectively. The terms on existing variable rate debt, including commercial paper, approximate current market conditions; therefore, the fair values of these instruments approximate their carrying values. The Company has assigned the long-term debt a Level 2 fair value measurement, as more fully described in Note 11, Fair Value Measurements.




29



NOTE 14 - GOODWILL AND INTANGIBLE ASSETS

A reconciliation of changes in the Company’s goodwill is as follows:

(in thousands)
Dental Consumable and Laboratory Businesses
 
Orthodontics/Canada/Mexico/Japan
 
Select Distribution Businesses
 
Implants/Endodontics/Healthcare/Pacific Rim
 
Total
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2011
$
484,779

 
$
102,950

 
$
108,566

 
$
1,493,768

 
$
2,190,063

Adjustment of provisional amounts on prior acquisition

 

 

 
(144,530
)
 
(144,530
)
Business unit transfer

 

 
2,132

 
(2,132
)
 

Effects of exchange rate changes
(2,054
)
 
(641
)
 
(6,602
)
 
(152
)
 
(9,449
)
Balance at June 30, 2012
$
482,725

 
$
102,309

 
$
104,096

 
$
1,346,954

 
$
2,036,084


Identifiable definite-lived and indefinite-lived intangible assets consist of the following:

 
June 30, 2012
 
December 31, 2011
(in thousands) 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
 
 
 
 
 
 
 
 
 
 
 
 
Patents
$
129,570

 
$
(23,573
)
 
$
105,997

 
$
131,252

 
$
(17,393
)
 
$
113,859

Trademarks
85,228

 
(40,659
)
 
44,569

 
73,413

 
(23,885
)
 
49,528

Licensing agreements
30,412

 
(18,094
)
 
12,318

 
30,444

 
(17,277
)
 
13,167

Customer relationships
703,249

 
(137,130
)
 
566,119

 
411,626

 
(19,066
)
 
392,560

Total definite-lived
$
948,459

 
$
(219,456
)
 
$
729,003

 
$
646,735

 
$
(77,621
)
 
$
569,114

 
 
 
 
 
 
 
 
 
 
 
 
Trademarks
$
209,993

 
$

 
$
209,993

 
$
210,675

 
$

 
$
210,675

In-process R&D
8,751

 

 
8,751

 
11,311

 

 
11,311

Total indefinite-lived
$
218,744

 
$

 
$
218,744

 
$
221,986

 
$

 
$
221,986

 
 
 
 
 
 
 
 
 
 
 
 
Total identifiable intangible assets
$
1,167,203

 
$
(219,456
)
 
$
947,747

 
$
868,721

 
$
(77,621
)
 
$
791,100


NOTE 15 - COMMITMENTS AND CONTINGENCIES

Litigation

On June 18, 2004, Marvin Weinstat, DDS and Richard Nathan, DDS filed a class action suit in San Francisco County, California alleging that the Company misrepresented that its Cavitron® ultrasonic scalers are suitable for use in oral surgical procedures.   
The Complaint seeks a recall of the product and refund of its purchase price to dentists who have purchased it for use in oral surgery. The Court certified the case as a class action in June 2006 with respect to the breach of warranty and unfair business practices claims. The class that was certified is defined as California dental professionals who purchased and used one or more Cavitron® ultrasonic scalers for the performance of oral surgical procedures. The case is pending in the San Francisco County Court. As the result of several hearings, the Judge has held that the class period will be from June 2000 to the present. The Class Notice, once approved by the Court, will be mailed to dentists licensed to practice in California during the class period from June 2000 to the present.

On December 12, 2006, a Complaint was filed by Carole Hildebrand, DDS and Robert Jaffin, DDS in the Eastern District of Pennsylvania (the Plaintiffs subsequently added Dr. Mitchell Goldman as a named class representative).  The case was filed by the same law firm that filed the Weinstat case in California.  The Complaint asserts putative class action claims on behalf of dentists located in New Jersey and Pennsylvania. The Complaint seeks damages and asserts that the Company's Cavitron® ultrasonic

30



scaler was negligently designed and sold in breach of contract and warranty arising from misrepresentations about the potential uses of the product because it cannot assure the delivery of potable or sterile water. Plaintiffs have filed their motion for class certification to which the Company has filed its response. The Company also filed other motions, including a motion to dismiss the claims of Drs. Hildebrand and Jaffin for lack of standing. The Court granted this motion for lack of standing of the individuals and did not allow the plaintiffs to amend the complaint to substitute their corporate practices, leaving Dr. Goldman as the only putative class representative, raising a question of jurisdiction of the U.S. District Court. Subsequently, the Court issued an Order dismissing this case on the grounds that it did not have jurisdiction over the matter. The plaintiffs filed a second complaint (under the name “Center City Periodontists”) after the Court granted the initial Motion for lack of standing, in which they named the corporate practices of Drs. Hildebrand and Jaffin as class representatives. The Company has moved to dismiss this complaint and the Court has not yet ruled on this Motion.
 
The Company does not believe a loss is probable related to the above litigation. Further a reasonable estimate of a possible range of loss cannot be made.   In the event that one or more of these matters is unfavorably resolved, it is possible the Company's results from operations could be materially impacted.

Purchase Commitments

From time to time, the Company enters into long-term inventory purchase commitments with minimum purchase requirements for raw materials and finished goods to ensure the availability of products for production and distribution.  These commitments may have a significant impact on levels of inventory maintained by the Company.



31



DENTSPLY International Inc. and Subsidiaries

Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations

This report contains information that may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Generally, the use of terms such as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” and similar expressions identify forward-looking statements. All statements that address operating performance, events or developments that DENTSPLY International Inc. (“DENTSPLY” or the “Company”) expects or anticipates will occur in the future are forward-looking statements. Forward-looking statements are based on management's current expectations and beliefs, and are inherently susceptible to uncertainty, risks, and changes in circumstances that could cause actual results to differ materially from the Company's historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in Part I, Item 1A (“Risk Factors”) of the Company's Form 10-K for the year ended December 31, 2011 and those described from time to time in our future reports filed with the Securities and Exchange Commission. The Company undertakes no duty and has no obligation to update forward-looking statements as a result of future events or developments.

OVERVIEW

Quarter Highlights

In the three months ended June 30, 2012, the Company achieved record second quarter sales. Sales in the period grew by 25.2% on a US GAAP reported basis and grew 23.8%, excluding precious metal content. The sales growth excluding precious metal content was driven by acquisition growth of 26.4%, while internal growth added 3.6%, and currency translation was negative 6.2%. Internal growth excluding Orthodontics and our businesses in Japan was 3.9%. This internal growth was comprised of growth in the United States of 2.9%, while Europe reported 2.6% and rest of world had 8.1%.

The Company is proceeding with its integration efforts for the Astra Tech acquisition that was completed on August 31, 2011. During the quarter the Company completed the integration of the dental implant organization in the United States. The Company expects to complete integration activities in several countries throughout Europe during the remaining quarters in 2012 and early 2013.

The Company's Orthodontics recovery plan is also proceeding. The supply situation has continued to improve, and more complete shipments are being received. The impact on year-over-year earnings was neutral in the second quarter and approximately a negative $0.04 per diluted share in the first six months of 2012. The earnings impact is expected to continue to be positive on a year-over-year basis in the third and fourth quarters of 2012.

The rapid strengthening of the U.S. dollar has negatively impacted top-line sales growth and earnings per share and is expected to continue to have a negative impact through the third and fourth quarter of 2012.

Company Profile

DENTSPLY International Inc. is a leading manufacturer and distributor of dental and other healthcare products.  The Company believes it is the world's largest manufacturer of professional dental products.  For over 110 years, DENTSPLY's commitment to innovation and professional collaboration has enhanced its portfolio of branded consumables and small equipment.  Headquartered in the United States, the Company has global operations with sales in more than 120 countries. The Company also has strategically located distribution centers to enable it to better serve its customers and increase its operating efficiency. While the United States and Europe are the Company's largest markets, the Company serves all major markets worldwide.

Principal Products

The Company has four main product categories: 1) Dental Consumable Products; 2) Dental Laboratory Products; 3) Dental Specialty Products; and 4) Consumable Medical Device Products.

Dental consumable products consist of dental sundries and small equipment used in dental offices by general practitioners in the treatment of patients. The Company manufactures a wide variety of different dental sundry consumable products marketed under more than one hundred brand names.  DENTSPLY’s dental sundry products within this category include dental anesthetics, prophylaxis paste, dental sealants, impression materials, restorative materials, tooth whiteners and topical fluoride.  Small equipment products in the dental consumable category consist of various durable goods used in dental offices for treatment of

32



patients.  DENTSPLY’s small equipment products include high and low speed handpieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Dental laboratory products are used in the preparation of dental appliances by dental laboratories.  DENTSPLY’s products within this category include dental prosthetics, artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials.  This category also includes fabricated dental appliances, computer aided design software and centralized manufacturing of frameworks. Equipment in this category includes computer aided machining ceramic systems and porcelain furnaces.

Dental specialty products are specialized treatment products used within the dental office and laboratory settings.  DENTSPLY’s products within this category include endodontic instruments and materials, implants and related products, bone grafting materials, 3D digital implantology, dental lasers and orthodontic appliances and accessories.

Consumable medical device products consist mainly of urological products including catheters, certain surgical products, medical drills and other non-medical products.

Principal Measurements

The principal measurements used by the Company in evaluating its business are: (1) internal growth by geographic region; (2) constant currency growth by geographic region; (3) operating margins of each reportable segment including product pricing and cost controls; (4) the development, introduction and contribution of innovative new products; and (5) growth through acquisition.

The Company defines “internal growth” as the increase or decrease in net sales from period to period, excluding (1) precious metal content; (2) the impact of changes in currency exchange rates; and (3) net acquisition growth. The Company defines “net acquisition growth” as the net sales for a period of twelve months following the transaction date of businesses that have been acquired, less the net sales for a period of twelve months prior to the transaction date of businesses that have been divested. The Company defines “constant currency growth” as internal growth plus net acquisition growth.

Management believes that an average internal growth rate of 4% to 6% is a long-term targeted rate for the Company. The internal growth rate may vary outside of this range based on weaker or stronger economic conditions.  Management believes the Company may operate below this range for 2012 primarily due to the economic uncertainty in Europe and impact on the global economies.  There can be no assurance that the Company’s assumptions concerning the growth rates in its markets will continue in the future.  If such rates are less than expected, the Company’s projected growth rates and results of operations may be adversely affected.

Price changes, other marketing and promotional programs offered to customers from time to time, the management of inventory levels by distributors and the implementation of strategic initiatives may impact sales and inventory levels in a given period.

The Company has always maintained a focus on minimizing costs and achieving operational efficiencies. Management continues to evaluate the consolidation of operations or functions to reduce costs. In addition, the Company remains focused on enhancing efficiency through expanded use of technology and process improvement initiatives. The Company believes that the benefits from these initiatives will improve the cost structure and help offset areas of rising costs such as energy, employee benefits and regulatory oversight and compliance.

Product innovation is a key component of the Company's overall growth strategy. New advances in technology are anticipated to have a significant influence on future products in dentistry. As a result, the Company continues to pursue research and development initiatives to support technological development, including collaborations with various research institutions and dental schools. In addition, the Company licenses and purchases technologies developed by third parties. Although the Company believes these activities will lead to new innovative dental products, they involve new technologies and there can be no assurance that commercialized products will be developed.

The Company will continue to pursue opportunities to expand the Company's product offerings through acquisitions. Although the professional dental and the consumable medical device markets in which the Company operates has experienced consolidation, it is still a fragmented industry. Management believes that there will continue to be adequate opportunities to participate as a consolidator in the industry for the foreseeable future, however it will be very focused in the near-term on the integration of recent acquisitions and associated debt reduction.




33



Impact of the Natural Disaster in Japan

 The Company's Orthodontic and Japanese businesses have been negatively impacted as a result of the natural disaster that occurred in Japan in March of 2011. The Company's Orthodontic business has a key supplier located in Japan whose manufacturing was substantially curtailed as a result of the natural disaster. The supplier is now operating at a new location and is improving supply delivery. As a result, the Company's sales of orthodontic products were nearly flat for the three months end June 30, 2012 as compared with the three months ended June 30, 2011, resulting in a neutral impact to the period's year-over-year earnings. Sales were down 15.8% for the first six months of 2012 as compared with the same period of 2011, resulting in a negative impact on earnings of approximately $0.04 per diluted share. The Company is receiving increased shipments of components from its supplier in Japan and expects to show positive quarter over quarter results in the third quarter. The Company expects this business to show a slightly improved year-over-year comparison for 2012. The Company has begun the re-launch of several of the affected product lines.

Impact of Foreign Currencies

Due to the international nature of DENTSPLY's business, movements in foreign exchange rates may impact the consolidated statements of operations. With over 69% of the Company's sales located in regions outside the United States, the Company's consolidated net sales are impacted negatively by the strengthening or positively by the weakening of the U.S. dollar. Additionally, movements in certain foreign exchange rates may unfavorably or favorably impact the Company's results of operations, financial condition and liquidity.

RESULTS OF OPERATIONS, QUARTER ENDED JUNE 30, 2012 COMPARED TO QUARTER ENDED JUNE 30, 2011

Net Sales

Management believes that the presentation of net sales, excluding precious metal content, provides useful information to investors because a significant portion of DENTSPLY’s net sales is comprised of sales of precious metals generated through sales of the Company’s precious metal dental alloy products, which are used by third parties to construct crown and bridge materials.  Due to the fluctuations of precious metal prices and because the precious metal content of the Company’s sales is largely a pass-through to customers and has minimal effect on earnings, DENTSPLY reports net sales both with and without precious metal content to show the Company’s performance independent of precious metal price volatility and to enhance comparability of performance between periods.  The Company uses its cost of precious metal purchased as a proxy for the precious metal content of sales, as the precious metal content of sales is not separately tracked and invoiced to customers.  The Company believes that it is reasonable to use the cost of precious metal content purchased in this manner since precious metal dental alloy sale prices are typically adjusted when the prices of underlying precious metals change.

The presentation of net sales, excluding precious metal content, is considered a measure not calculated in accordance with the generally accepted accounting principles in the United States (“US GAAP”), and is therefore considered a non-US GAAP measure.  The Company provides the following reconciliation of net sales to net sales, excluding precious metal content.  The Company’s definitions and calculations of net sales, excluding precious metal content, and other operating measures derived using net sales, excluding precious metal content, may not necessarily be the same as those used by other companies.

 
Three Months Ended
 
 
 
 
 
June 30,
 
 
(in millions)
2012
 
2011
 
$ Change
 
% Change
 
 
 
 
 
 
 
 
Net sales
$
763.0

 
$
609.4

 
$
153.6

 
25.2
%
Less: precious metal content of sales
64.5

 
45.4

 
19.1

 
42.1
%
Net sales, excluding precious metal content
$
698.5

 
$
564.0

 
$
134.5

 
23.8
%


Net sales, excluding precious metal content, for the three months ended June 30, 2012 was $698.5 million, an increase of 23.8% over the second quarter of 2011.  The change in net sales, excluding precious metal content, was primarily a result of the acquisition growth of $148.9 million, or 26.4%.  Foreign currency translation negatively impacted sales growth by 6.2%.   Internal growth was 3.6% and excluding sales in the Japanese market and Orthodontic businesses, internal growth was 3.9%.



34



Constant Currency and Internal Sales Growth

The following table includes growth rates for net sales, excluding precious metal content, for the three months ended June 30, 2012 compared with the three months ended June 30, 2011.

 
Three Months Ended June 30, 2012
 
United
States
 
Europe
 
All Other
Regions
 
Worldwide
 
 
 
 
 
 
 
 
Internal sales growth
1.0
%
 
2.8
%
 
8.6
%
 
3.6
%
Acquisition sales growth
15.2
%
 
43.0
%
 
14.3
%
 
26.4
%
Constant currency sales growth
16.2
%
 
45.8
%
 
22.9
%
 
30.0
%
Adjusted internal sales growth (a)
2.9
%
 
2.6
%
 
8.1
%
 
3.9
%
(a) Excludes Japanese market and Orthodontic business.

United States

Net sales, excluding precious metal content, increased by 16.2% for the second quarter of 2012 compared to the second quarter of 2011 on a constant currency basis, including 15.2% of acquisition growth and 1.0% of internal sales growth.  Excluding the orthodontic business, the internal growth rate in the United States was 2.9%. This adjusted internal growth rate was a result of growth across all product categories.

Europe

Net sales, excluding precious metal content, increased by 45.8% in the second quarter of 2012 on a constant currency basis, including 2.8% of internal sales growth.  Excluding the orthodontic business, the internal growth rate was 2.6% and was the result of increased demand for dental specialty and dental consumables products, partially offset by decreased sales of precious metal alloy products in the dental laboratory products.

All Other Regions

Net sales, excluding precious metal content, in the other regions of the world increased by 22.9% on a constant currency basis, which includes 8.6% of internal sales growth.  Excluding the Japanese market and orthodontic business, the resulting internal growth was 8.1%.  This adjusted internal growth was led by growth primarily in dental specialty products.

Gross Profit

 
Three Months Ended
 
 
 
 
 
June 30,
 
 
 
 
(in millions)
2012
 
2011
 
$ Change
 
% Change
 
 
 
 
 
 
 
 
Gross profit
$
407.5

 
$
314.9

 
$
92.6

 
29.4
%
Gross profit as a percentage of net sales, including precious metal content
53.4
%
 
51.7
%
 
 

 
 

Gross profit as a percentage of net sales, excluding precious metal content
58.3
%
 
55.8
%
 
 

 
 


Gross profit as a percentage of net sales, excluding precious metal content, increased by 2.5 percentage points for the three months ended June 30, 2012 compared to the same quarter of 2011.   The margin rate was primarily impacted by positive manufacturing performance, foreign currency impacts, as well as favorable product mix, including the mix of recent acquisitions and product pricing.






35



Operating Expenses

 
Three Months Ended
 
 
 
 
 
June 30,
 
 
 
 
(in millions)
2012
 
2011
 
$ Change
 
% Change
 
 
 
 
 
 
 
 
Selling, general and administrative expenses (“SG&A”)
$
296.0

 
$
211.0

 
$
85.0

 
40.3
%
Restructuring and other costs
$
2.5

 
$
6.9

 
$
(4.4
)
 
NM

 
 
 
 
 
 
 
 
SG&A as a percentage of net sales, including precious metal content
38.8
%
 
34.6
%
 
 

 
 

SG&A as a percentage of net sales, excluding precious metal content
42.4
%
 
37.4
%
 
 

 
 

NM – Not meaningful

SG&A Expenses

SG&A expenses as a percentage of net sales, excluding precious metal content, increased in the quarter end June 30, 2012 by 5.0 percentage points when compared to the same quarter of 2011.  Increased expenses as a percent of net sales, excluding precious metal content, over the prior year is primarily a result of the higher expense rate of the Astra Tech business, and $8.3 million of amortization primarily associated with intangible assets from 2011 acquisitions and expenses associated with key global marketing events. The second quarter of 2012 also included $4.4 million for expenses related to integration costs. The second quarter of 2011 included $0.6 million of amortization expense related to acquired intangible assets. 

Restructuring and Other Costs

During the three months ended June 30, 2012, the Company recorded restructuring and other costs of $2.5 million.   In the same period of 2011, the Company incurred costs of $6.9 million. (See also Note 9, Restructuring and Other Costs, of the Notes to Unaudited Interim Consolidated Financial Statements).

Other Income and Expense
 
Three Months Ended
June 30,
 
 
(in millions)
2012
 
2011
 
Change
 
 
 
 
 
 
Net interest expense
$
12.6

 
$
3.1

 
$
9.5

Other expense (income), net
0.7

 
1.4

 
(0.7
)
Net interest and other expense
$
13.3

 
$
4.5

 
$
8.8


Net Interest Expense

Net interest expense for the three months ended June 30, 2012 was $9.5 million higher compared to the three months ended June 30, 2011. The increase is due to increased interest expense as a result of higher overall debt in support of recent acquisitions.














36



Income Taxes and Net Income
  
 
Three Months Ended
June 30,
 
 
(in millions, except per share data)
2012
 
2011
 
$ Change
 
 
 
 
 
 
Effective income tax rates
15.6
%
 
19.4
%
 
 
 
 
 
 
 
 
Equity in net income (loss) of unconsolidated affiliated company
$
1.3

 
$
0.9

 
$
0.4

 
 
 
 
 
 
Net income attributable to noncontrolling interests
$
1.3

 
$
1.2

 
$
0.1

 
 
 
 
 
 
Net income attributable to DENTSPLY International
$
80.8

 
$
74.2

 
$
6.6

 
 
 
 
 
 
Earnings per common share - diluted
$
0.56

 
$
0.52

 
 


 Provision for Income Taxes

The Company's effective tax rates for the second quarter of 2012 and 2011 were 15.6% and 19.4%, respectively. The effective tax rate for 2012 is favorably impacted by the Company's favorable resolution of tax contingencies, change in assumptions surrounding the repatriation of foreign earnings into the United States, acquisition restructuring activities, as well as an improvement from the mix of consolidated earnings.

The Company’s effective income tax rate for 2012 also included the impact of amortization on purchased intangibles assets, integration and restructuring and other costs and various income tax adjustments which impacted income before income taxes and the provision for income taxes by $20.7 million and $12.0 million, respectively.  In 2011, the Company’s effective income tax rate included the impact of acquisition related activity, restructuring and other costs, income related to a credit risk adjustment on outstanding derivatives and various income tax adjustments which impacted income before income taxes and the provision for income taxes by $6.7 million and $1.7 million, respectively.

Equity in net income (loss) of unconsolidated affiliated company

The Company’s 17% ownership investment of DIO Corporation resulted in income of $1.3 million on an after-tax basis for the three months ended June 30, 2012.  The net income of DIO includes the result of a positive fair value adjustment related to the convertible bonds issued by DIO to DENTSPLY.  The fair value adjustments related to the convertible bonds reported by DIO are primarily impacted by changes in the DIO share price.  The impact of changes in the DIO share price on the fair value adjustment for the three months ended June 30, 2012 and 2011 was income of approximately $1.0 million and $1.2 million, respectively.

Net Income attributable to DENTSPLY International

In addition to the results reported in accordance with US GAAP, the Company provides adjusted net income attributable to DENTSPLY International and adjusted earnings per diluted common share.  These adjusted amounts consist of US GAAP amounts excluding, net of tax (1) acquisition related costs, (2) restructuring and other costs, (3) amortization of purchased intangible assets, (4) Orthodontic business continuity costs, (5) income related to credit risk adjustments, (6) certain fair value adjustments at an unconsolidated affiliated company, and (7) income tax related adjustments. Adjusted earnings per diluted common share is calculated by dividing adjusted net income attributable to DENTSPLY International by diluted weighted-average common shares outstanding. Adjusted net income attributable to DENTSPLY International and adjusted earnings per diluted common share are considered measures not calculated in accordance with US GAAP, and therefore are non-US GAAP measures.  These non-US GAAP measures may differ from other companies. Income tax related adjustments may include the impact to adjust the interim effective income tax rate to the expected annual effective tax rate.

The Company believes that the presentation of adjusted net income attributable to DENTSPLY International and adjusted earnings per diluted common share provides important supplemental information to management and investors seeking to understand the Company's financial condition and results of operations.  The non-US GAAP financial information should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP.


37



 
Three Months Ended June 30, 2012
(in thousands, except per share amounts)
Income
(Expense)
 
Per Diluted
Common Share
 
 
 
 
Net income attributable to DENTSPLY International
$
80,764

 
$
0.56

Amortization of purchased intangible assets, net of tax
9,007

 
0.06

Acquisition related activities, net of tax
2,993

 
0.02

Restructuring and other costs, net of tax  
1,990

 
0.02

Orthodontics business continuity costs, net of tax
213

 

Gain on fair value adjustments at an unconsolidated affiliated company, net of tax
(1,060
)
 
(0.01
)
Income tax related adjustments
(5,380
)
 
(0.03
)
Adjusted non-US GAAP earnings
$
88,527

 
$
0.62


 
Three Months Ended June 30, 2011
(in thousands, except per share amounts)
Income
(Expense)
 
Per Diluted
Common Share
 
 
 
 
Net income attributable to DENTSPLY International
$
74,236

 
$
0.52

Acquisition related activities, net of tax
6,164

 
0.04

Amortization of purchased intangible assets, net of tax
1,497

 
0.01

Restructuring and other costs, net of tax
591

 
0.01

Orthodontics business continuity costs, net of tax
442

 
0.01

Credit risk adjustment to outstanding derivatives, net of tax
(783
)
 
(0.01
)
Income tax related adjustments
(977
)
 
(0.01
)
Loss on fair value adjustments at an unconsolidated affiliated company, net of tax
(1,180
)
 
(0.01
)
Adjusted non-US GAAP earnings
$
79,990

 
$
0.56


Operating Segment Results

Third Party Net Sales, Excluding Precious Metal Content
 
Three Months Ended
 
 
 
 
 
June 30,
 
 
(in millions)
2012
 
2011
 
$ Change
 
% Change
 
 
 
 
 
 
 
 
Dental Consumable and Laboratory Businesses
$
206.9

 
$
214.2

 
$
(7.3
)
 
(3.4
)%
 
 
 
 
 
 
 
 
Orthodontics/Canada/Mexico/Japan
$
77.0

 
$
77.4

 
$
(0.4
)
 
(0.5
)%
 
 
 
 
 
 
 
 
Select Distribution Businesses
$
77.1

 
$
80.5

 
$
(3.4
)
 
(4.2
)%
 
 
 
 
 
 
 
 
Implants/Endodontics/Healthcare/Pacific Rim
$
340.3

 
$
193.5

 
$
146.8

 
75.9
 %








38



Segment Operating Income
 
Three Months Ended
 
 
 
 
 
June 30,
 
 
(in millions)
2012
 
2011
 
$ Change
 
% Change
 
 
 
 
 
 
 
 
Dental Consumable and Laboratory Businesses
$
63.3

 
$
61.5

 
$
1.8

 
2.9
 %
 
 
 
 
 
 
 
 
Orthodontics/Canada/Mexico/Japan
$
3.9

 
$
4.3

 
$
(0.4
)
 
(9.3
)%
 
 
 
 
 
 
 
 
Select Distribution Businesses
$
0.1

 
$
0.6

 
$
(0.5
)
 
NM

 
 
 
 
 
 
 
 
Implants/Endodontics/Healthcare/Pacific Rim
$
77.2

 
$
63.2

 
$
14.0

 
22.2
 %
NM – Not meaningful

Dental Consumable and Laboratory Businesses

Net sales, excluding precious metal content, decreased $7.3 million, or 3.4%, during the three months ended June 30, 2012 compared to 2011.  On a constant currency basis, net sales, excluding precious metal content, increased 1.2%.  This increase was primarily the result of higher demand in dental consumables businesses partially offset by lower sales of precious metal alloy products in the dental laboratory businesses.

Operating income increased by 2.9% during the three months ended June 30, 2012 compared to 2011.  Gross profit decreased by $2.0 million as a result of unfavorable currency translation.  SG&A expenses decreased by $3.8 million due to the favorable impact of currency translation.

Orthodontics/Canada/Mexico/Japan

Net sales, excluding precious metal content, decreased by $0.4 million during the three months ended June 30, 2012 compared to 2011. On a constant currency basis, net sales, excluding precious metal content, increased 2.5% due to stronger dental consumable sales, while the sales in the orthodontic businesses were nearly flat with the prior year period.

Operating income decreased $0.4 million compared to the same year ago period. Selling, general and administrative expenses increased $0.9 million partially offset by gross profit improvements.

Select Distribution Businesses

Net sales, excluding precious metal content, decreased $3.4 million, or 4.2%, during the three months ended June 30, 2012 compared to 2011.  On a constant currency basis, net sales, excluding precious metal content, increased 8.3% when compared to the same period of 2011.  The growth was primarily related to increased sales of dental consumables and dental specialty products.

Operating income decreased $0.5 million during the three months ended June 30, 2012 compared to 2011.  Gross profit decreased $3.8 million, primarily as a result of unfavorable currency translation.   SG&A expenses decreased by $3.3 million, primarily due to the favorable impact of currency translation.

Implants/Endodontics/Healthcare/Pacific Rim

Net sales, excluding precious metal content, increased $146.8 million, or 75.9%, during the three months ended June 30, 2012 compared to 2011.  On a constant currency basis, net sales, excluding precious metal content, increased 82.4% primarily driven by acquisitions, coupled with solid internal growth.

Operating income for the three months ended June 30, 2012 increased $14.0 million or 22.2%, compared to 2011. Gross profit increased $99.0 million primarily due to acquisitions and constant currency sales growth, partially offset by the unfavorable impact of currency translation. SG&A expenses increased $85.0 million primarily due to acquisitions partially offset by $12.2 million in favorable impact of currency translation.



39



RESULTS OF OPERATIONS, SIX MONTHS ENDED JUNE 30, 2012 COMPARED TO SIX MONTHS ENDED JUNE 30, 2011

Net Sales
    
The following is a reconciliation of net sales to net sales, excluding precious metals content.
 
Six Months Ended
 
 
 
 
 
June 30,
 
 
(in millions)
2012
 
2011
 
$ Change
 
% Change
 
 
 
 
 
 
 
 
Net sales
$
1,479.4

 
$
1,179.9

 
$
299.5

 
25.4
%
Less: precious metal content of sales
115.3

 
88.9

 
26.4

 
29.7
%
Net sales, excluding precious metal content
$
1,364.1

 
$
1,091.0

 
$
273.1

 
25.0
%

Net sales, excluding precious metal content, for the six months ended June 30, 2012 was $1,364.1 million, an increase of 25.0% over the same period of 2011. The change in net sales, excluding precious metal content, was the result of constant currency growth of 29.2% and acquisition growth of 26.8%. The constant currency sales growth included internal growth of 2.4%. Excluding the Japanese market and the Orthodontic business, the internal growth rate was 4.2%.

Constant Currency and Internal Sales Growth
    
The following table includes growth rates for net sales, excluding precious metal content for the six months ended June 30, 2012 compared with the six months ended June 30, 2011.

 
Six Months Ended June 30, 2012
 
United
States
 
Europe
 
All Other
Regions
 
Worldwide
 
 
 
 
 
 
 
 
Internal sales growth
2.2
%
 
0.9
%
 
5.2
%
 
2.4
%
Acquisition sales growth
15.6
%
 
42.9
%
 
14.8
%
 
26.8
%
Constant currency sales growth
17.8
%
 
43.8
%
 
20.0
%
 
29.2
%
Adjusted internal sales growth (a)
5.1
%
 
2.4
%
 
6.4
%
 
4.2
%
(a) Excludes Japanese market and Orthodontic business.

United States

Net sales, excluding precious metal content, increased by 17.8% for the six months ended June 30, 2012 compared to the same period of 2011 on a constant currency basis, including acquisition growth of 15.6%. Excluding the Orthodontic business, the internal growth rate was 5.1%, primarily due to increases in dental specialty, dental consumables and dental laboratory product sales.

Europe

Net sales, excluding precious metal content, increased by 43.8% for the six months ended June 30, 2012 on a constant currency basis, including acquisition growth of 42.9%. Excluding the Orthodontic business, the internal growth rate was 2.4% and was primarily driven by growth in dental specialty and dental consumables products, partially offset by lower demand for dental laboratory products.

All Other Regions

Net sales, excluding precious metal content, in the other regions of the world increased by 20.0% on a constant currency basis, which includes 5.2% of internal growth. Excluding the Japanese market and Orthodontic business, internal growth was 6.4%, driven primarily by growth in dental specialty products, while sales in dental consumables and dental laboratory products grew slightly.



40



Gross Profit

 
Six Months Ended
 
 
 
 
 
June 30,
 
$
 
%
(in millions)
2012
 
2011
 
 Change
 
 Change
 
 
 
 
 
 
 
 
Gross profit
$
800.2

 
$
614.8

 
$
185.4

 
30.2
%
Gross profit as a percentage of net sales, including precious metal content
54.1
%
 
52.1
%
 
 

 
 

Gross profit as a percentage of net sales, excluding precious metal content
58.7
%
 
56.4
%
 
 

 
 


Gross profit as a percentage of net sales, excluding precious metal content, increased by 2.3 percentage points for the six months ended June 30, 2012 compared to the same period in 2011. The margin rate was primarily impacted by favorable mix associated with recent acquisitions, positive manufacturing costs, foreign currency translation, as well as product pricing.

Operating Expenses

 
Six Months Ended
 
 
 
 
 
June 30,
 
$
 
%
(in millions)
2012
 
2011
 
Change
 
 Change
 
 
 
 
 
 
 
 
Selling, general and administrative expenses (“SG&A”)
$
600.4

 
$
411.8

 
$
188.6

 
45.8
%
Restructuring and other costs
$
3.8

 
$
7.5

 
$
(3.7
)
 
NM

 
 
 
 
 
 
 
 
SG&A as a percentage of net sales, including precious metal content
40.6
%
 
34.9
%
 
 

 
 

SG&A as a percentage of net sales, excluding precious metal content
44.0
%
 
37.7
%
 
 

 
 

NM – Not meaningful

SG&A Expenses

SG&A expenses as a percentage of net sales, excluding precious metal content, increased for the six months ended June 30, 2012 by 6.3 percentage points when compared to the same period of 2011. Increased expenses as a percent of net sales, excluding precious metal content, over the prior year is primarily a result of the higher expense rate of the Astra Tech business and $20.3 million of amortization primarily associated with intangibles from 2011 acquisitions as well as additional expenses associated with key global marketing events. The for the six months ended 2012 also included $10.8 million for expenses related to integration costs. The for the six months ended 2011 included $1.2 million of amortization expense related to acquired intangible assets. 

Restructuring and Other Costs

During the six months ended June 30, 2012 and 2011, the Company recorded restructuring and other costs of $3.8 million and $7.5 million, respectively. (See also Note 9, Restructuring and Other Costs, of the Notes to Unaudited Interim Consolidated Financial Statements).

Other Income and Expense

 
Six Months Ended
June 30,
 
 
(in millions)
2012
 
2011
 
Change
 
 
 
 
 
 
Net interest expense
$
26.1

 
$
7.7

 
$
18.4

Other expense (income), net
1.2

 
1.5

 
(0.3
)
Net interest and other expense
$
27.3

 
$
9.2

 
$
18.1






41



Net Interest Expense

Net interest expense for the six months ended June 30, 2012 was $18.4 million higher compared to the six months ended June 30, 2011. The increase is due to increased interest expense as a result of higher overall debt in support of recent acquisitions.

Income Taxes and Net Income
  
 
Six Months Ended
June 30,
 
 
(in millions, except per share data)
2012
 
2011
 
$ Change
 
 
 
 
 
 
Effective income tax rates
17.5
%
 
22.4
%
 
 
 
 
 
 
 
 
Equity in net (loss) earnings of unconsolidated affiliated company
$
(2.9
)
 
$
0.1

 
$
(3.0
)
 
 
 
 
 
 
Net income attributable to noncontrolling interests
$
2.2

 
$
1.5

 
$
0.7

 
 
 
 
 
 
Net income attributable to DENTSPLY International
$
134.0

 
$
143.3

 
$
(9.3
)
 
 
 
 
 
 
Earnings per common share - diluted
$
0.93

 
$
1.00

 
 


Provision for Income Taxes

The Company's effective income tax rates for the first six months of 2012 and 2011 were 17.5% and 22.4%, respectively. The effective tax rate for 2012 is favorably impacted by the Company's favorable resolution of tax contingencies, change in assumptions surrounding the repatriation of foreign earnings into the United States, acquisition restructuring activities, as well as an improvement from the mix of consolidated earnings.

The Company's effective income tax rate for 2012 also included the impact of amortization on purchased intangibles assets, integration and restructuring and other costs and various income tax adjustments which impacted income before income taxes and the provision for income taxes by $46.3 million and $20.0 million, respectively. In 2011, the Company's effective income tax rate included the impact of acquisition related activity, restructuring and other costs, income related to a credit risk adjustment on outstanding derivatives and various income tax adjustments which impacted income before income taxes and the provision for income taxes by $7.3 million and $1.7 million, respectively.

Equity in net income (loss) of unconsolidated affiliated company

The Company's 17% ownership investment of DIO Corporation resulted in a net loss of $2.9 million on an after-tax basis for the six months ended June 30, 2012. The net income of DIO includes the result of a positive fair value adjustment related to the convertible bonds issued by DIO to DENTSPLY. The fair value adjustments related to the convertible bonds reported by DIO are primarily impacted by the changing DIO share price. The impact of the changing DIO share price on the fair value adjustment and the Company's portion of DIO's net income for the six months ended June 30, 2012 was income of approximately $3.5 million.


42




Net Income attributable to DENTSPLY International
 
In addition to the results reported in accordance with US GAAP, the Company provides adjusted net income attributable to DENTSPLY International and adjusted earnings per diluted common share.  These adjusted amounts consist of US GAAP amounts excluding (1) acquisition related costs and expensing of purchase price adjustments at an unconsolidated affiliated company, (2) restructuring and other costs, (3) Orthodontic business continuity costs, (4) certain fair value adjustment at an unconsolidated affiliated company, (5) income related to credit risk adjustments, and (6) income tax related adjustments.  Adjusted earnings per diluted common share is calculated by dividing adjusted net income attributable to DENTSPLY International by diluted weighted-average common shares outstanding. Adjusted net income attributable to DENTSPLY International and adjusted earnings per diluted common share are considered measures not calculated in accordance with US GAAP, and therefore are non-US GAAP measures.  These non-US GAAP measures may differ from other companies.

The Company believes that the presentation of adjusted net income attributable to DENTSPLY International and adjusted earnings per diluted common share provides important supplemental information to management and investors seeking to understand the Company's financial condition and results of operations.  The non-US GAAP financial information should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP.

 
Six Months Ended June 30, 2012
(in thousands, except per share amounts)
Income
(Expense)
 
Per Diluted
Common Share
 
 
 
 
Net income attributable to DENTSPLY International
$
134,049

 
$
0.93

Amortization of purchased intangible assets, net of tax
19,989

 
0.14

Acquisition related activities, net of tax
7,789

 
0.05

Loss on fair value adjustments at an unconsolidated affiliated company, net of tax
3,595

 
0.03

Restructuring and other costs, net of tax  
3,154

 
0.02

Orthodontics business continuity costs, net of tax
621

 

Income tax related adjustments
(5,414
)
 
(0.03
)
Adjusted non-US GAAP earnings
$
163,783

 
$
1.14


 
Six Months Ended June 30, 2011
(in thousands, except per share amounts)
Income
(Expense)
 
Per Diluted
Common Share
 
 
 
 
Net income attributable to DENTSPLY International
$
143,320

 
$
1.00

Acquisition related activities, net of tax
6,241

 
0.05

Amortization of purchased intangible assets, net of tax
3,006

 
0.02

Restructuring and other costs, net of tax  
874

 
0.01

Orthodontics business continuity costs, net of tax
442

 

Gain on fair value adjustments at an unconsolidated afflilated company
(260
)
 

Income tax related adjustments
(781
)
 
(0.01
)
Credit risk adjustment to outstanding derivatives, net of tax
(783
)
 
(0.01
)
Adjusted non-US GAAP earnings
$
152,059

 
$
1.06








43



Operating Segment Results

Third Party Net Sales, Excluding Precious Metal Content
 
Six Months Ended
 
 
 
 
 
June 30,
 
 
(in millions)
2012
 
2011
 
$ Change
 
% Change
 
 
 
 
 
 
 
 
Dental Consumable and Laboratory Businesses
$
414.3

 
$
415.3

 
$
(1.0
)
 
(0.2
)%
 
 
 
 
 
 
 
 
Orthodontics/Canada/Mexico/Japan
$
142.9

 
$
157.9

 
$
(15.0
)
 
(9.5
)%
 
 
 
 
 
 
 
 
Select Distribution Businesses
$
148.8

 
$
152.5

 
$
(3.7
)
 
(2.4
)%
 
 
 
 
 
 
 
 
Implants/Endodontics/Healthcare/Pacific Rim
$
662.3

 
$
367.9

 
$
294.4

 
80.0
 %

Segment Operating Income
 
Six Months Ended
 
 
 
 
 
June 30,
 
 
(in millions)
2012
 
2011
 
$ Change
 
% Change
 
 
 
 
 
 
 
 
Dental Consumable and Laboratory Businesses
$
124.8

 
$
117.5

 
$
7.3

 
6.2
 %
 
 
 
 
 
 
 
 
Orthodontics/Canada/Mexico/Japan
$
4.3

 
$
13.6

 
$
(9.3
)
 
(68.4
)%
 
 
 
 
 
 
 
 
Select Distribution Businesses
$
(0.9
)
 
$
0.4

 
$
(1.3
)
 
NM

 
 
 
 
 
 
 
 
Implants/Endodontics/Healthcare/Pacific Rim
$
143.4

 
$
117.6

 
$
25.8

 
21.9
 %
NM – Not meaningful

Dental Consumable and Laboratory Businesses

Net sales, excluding precious metal content, decreased $1.0 million during the six months ended June 30, 2012 compared to 2011. On a constant currency basis, net sales, excluding precious metal content, increased 3.0% which was primarily driven by increased demand in dental consumable products.

Operating income increased $7.3 million during the six months ended June 30, 2012 compared to 2011. This was due to a decrease in the selling, general and administrative expenses within the segment of $5.6 million, primarily due to favorable foreign currency translation, and an increase in gross profit of $1.6 million that includes $7.8 million of unfavorable foreign currency translation.

Orthodontics/Canada/Mexico/Japan

Net sales, excluding precious metal content, and operating income decreased $15.0 million and $9.3 million, respectively, during the six months ended June 30, 2012 compared to 2011. The decrease was primarily related to the impact of the natural disaster in Japan as previously discussed.

Select Distribution Businesses

Net sales, excluding precious metal content, decreased $3.7 million, or 2.4%, during the six months ended June 30, 2012 compared to 2011. On a constant currency basis, net sales, excluding precious metal content, increased 6.5% when compared to the same period in 2011 as a result of increased demand in dental specialty and dental consumable products.




44



Operating income decreased $1.3 million during the six months ended June 30, 2012 compared to 2011. The decline was attributable to a lower gross profit of $3.9 million, which was the result of unfavorable currency translation. Selling, general and administrative expenses decreased $2.6 million in the same period compared to 2011 due to favorable currency translation.

Implants/Endodontics/Healthcare/Pacific Rim

Net sales, excluding precious metal content, increased $294.4 million, or 80.0%, during the six months ended June 30, 2012 compared to 2011. On a constant currency basis, net sales, excluding precious metal content, increased 84.2% primarily driven by acquisitions, coupled with solid internal growth.

Operating income for the six months ended June 30, 2012 increased $25.8 million compared to 2011. Gross profit increased $204.3 million as a result of acquisitions and lower manufacturing costs partially offset by unfavorable foreign currency translation. Selling, general and administrative expenses increased by $178.6 million primarily due to acquisitions, partially offset by favorable currency translation.

CRITICAL ACCOUNTING POLICIES

Except as noted below, there have been no other significant material changes to the critical accounting policies as disclosed in the Company’s Form 10-K for the year ended December 31, 2011.

The Company has a note receivable from a borrower with a carrying value of $5.8 million, recorded as a component of other noncurrent assets, where the borrower has experienced recent financial deterioration.  A significant downturn or further deterioration in the creditworthiness of the borrower may negatively affect the Company's carrying value of the note receivable.

Annual Goodwill Impairment Testing

Goodwill is not amortized; instead, it is tested for impairment annually or more frequently if indicators of impairment exist or if a decision is made to sell a business. The valuation date for annual impairment testing is April 30. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include a decline in expected cash flows, a significant adverse change in legal factors or in the business climate, unanticipated competition or slower growth rates, among others. It is important to note that fair values that could be realized in an actual transaction may differ from those used to evaluate the impairment of goodwill.

Goodwill is allocated among and evaluated for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment. The Company has thirteen reporting units.

The evaluation of impairment involves comparing the current fair value of each reporting unit to its net book value, including goodwill. The Company uses a discounted cash flow model ("DCF model") to estimate the current fair value of its reporting units when testing for impairment, as management believes forecasted operating cash flows are the best indicator of such fair value. A number of significant assumptions and estimates are involved in the application of the DCF model to forecast operating cash flows, including future sales growth, operating margin growth, benefits from restructuring initiatives, tax rates, capital spending, business initiatives, and working capital changes. These assumptions may vary significantly among the reporting units. Operating cash flow forecasts are based on approved business-unit operating plans for the early years and historical relationships and projections in later years. The weighted average cost of capital ("WACC") rate is estimated for geographic regions and applied to the reporting units located within the regions. The Company has not materially changed its methodology for goodwill impairment testing for the years presented. Due to the many variables inherent in the estimation of a reporting unit's fair value and the relative size of the Company's recorded goodwill, differences in assumptions may have a material effect on the results of the Company's impairment analysis.

The performance of the Company's 2012 annual impairment tests did not result in any impairment of the Company's goodwill. The WACC rates utilized in the 2012 analysis ranged from 8.5% to 10.5%. Excluding the Company's Healthcare reporting unit discussed below, if the fair value of each of the Company's other reporting units been hypothetically reduced by 5% at April 30, 2012 the fair value of those reporting units would still exceed their net book value. If the fair value of each of the Company's reporting units been hypothetically reduced by 10% at April 30, 2012, one reporting unit within the Implants/Endodontics/Healthcare/Pacific Rim segment would have a net book value exceeding its fair value by less than $1.0 million. Goodwill for this reporting unit totals $24.1 million. Had the WACC rate of each of the Company's reporting units been hypothetically increased by 50 basis points at April 30, 2012, the fair value of all reporting units except for the Company's Healthcare reporting unit would still exceed their net book value. The Company's Healthcare reporting unit, a component of the Implants/Endodontics/Healthcare/Pacific Rim operating segment, was created as a part of the Astra Tech acquisition on August 31, 2011. At the date of acquisition,

45



the fair value of the business equaled book value with preliminary good will for the reporting unit totaling $279.0 million. Given the limited time since the acquisition date, the reporting unit fair value approximates the book value of the reporting unit.

Should the Company's analysis in the future indicate an increase in discount rates or a degradation in the overall markets served by these reporting units, it could result in impairment of the carrying value of goodwill to its implied fair value. There can be no assurance that the Company's future goodwill impairment testing will not result in a charge to earnings.

LIQUIDITY AND CAPITAL RESOURCES

Six months ended June 30, 2012

Cash flow from operating activities during the six months ended June 30, 2012 was $103.4 million compared to $166.5 million during the six months ended June 30, 2011. Net income decreased by $8.6 million to $136.3 million in the six month period ended June 30, 2012. Depreciation and amortization expense for the six months was $33.7 million higher than the prior year period. Working capital investments in inventory, prepaid expenses, and  accounts receivable, offset by higher tax accruals, were $92.2 million greater in the current six month period than the same period in the prior year and includes the effect of recent acquisitions. On a constant currency basis, at June 30, 2012, reported days for inventory increased by 11 days to 111 days and accounts receivable increased by 1 days to 55 days, respectively, as compared to December 31, 2011. The increase in days of inventory reflects the addition of the Astra Tech inventory, the build of Orthodontic inventory to support the re-launch of the product line and additional inventory to support other key product lines.

Investing activities during the first six months of 2012 include capital expenditures of $42.9 million. The Company expects capital expenditures to be higher than 2011 as the Company supports expanded business needs of recent acquisitions and key growth initiatives.

At June 30, 2012, the Company had authorization to maintain up to 34.0 million shares of treasury stock under the stock repurchase program as approved by the Board of Directors. Under this program, the Company purchased 1.0 million shares for $38.8 million during the first six months of 2012 at an average price of $38.90. At June 30, 2012, the Company held 21.0 million shares of treasury stock. The Company also received proceeds of $20.1 million as a result of the exercise of 0.9 million of stock options during the six months ended June 30, 2012.

The Company's total borrowings decreased by a net of $42.1 million during the six months ended June 30, 2012. This change included net decrease of $35.5 million during the first six months from repayments and a decrease of $6.6 million due to exchange rate fluctuations on debt denominated in foreign currencies. At June 30, 2012, the Company's ratio of total debt to total capitalization was 46.4% compared to 48.4% at December 31, 2011. Also in that same period, the Company's cash and cash equivalents have decreased from $77.1 million to $53.2 million.

Under its five-year multi-currency revolving credit agreement, the Company is able to borrow up to $500.0 million through July 27, 2016. Under its 364-day revolving credit agreement, the Company is able to borrow up to $250.0 million through August 29, 2012. These facilities are unsecured and contain certain affirmative and negative covenants relating to the operations and financial condition of the Company. The most restrictive of these covenants pertain to asset dispositions and prescribed ratios of indebtedness to total capital and operating income plus depreciation and amortization to interest expense. At June 30, 2012, the Company was in compliance with these covenants. The Company also has available an aggregate $500.0 million under a U.S. dollar commercial paper facility. Both the 364-day and the five-year revolvers serve as a back-up to the commercial paper facility, thus the total available credit under the commercial paper facility and the multi-currency revolving credit facilities in the aggregate is $750.0 million. At June 30, 2012, outstanding borrowings were $228.9 million under the multi-currency revolving facility.

The Company also has access to $74.0 million in uncommitted short-term financing under lines of credit from various financial institutions. The lines of credit have no major restrictions and are provided under demand notes between the Company and the lending institutions. At June 30, 2012, the Company had $11.7 million outstanding under these short-term lines of credit. At June 30, 2012, the Company had total unused lines of credit related to the revolving credit agreement and the uncommitted short-term lines of credit of $583.3 million.

At June 30, 2012, the Company held $123.4 million of precious metals on consignment from several financial institutions. The consignment agreements allow the Company to acquire the precious metal at market rates at a point in time which is approximately the same time and for the same price as alloys are sold to the Company's customers. In the event that the financial institutions would discontinue offering these consignment arrangements, and if the Company could not obtain other comparable arrangements, the Company may be required to obtain third party financing to fund an ownership position in the required precious metal inventory levels.

46




There have been no material changes to the Company's scheduled contractual cash obligations disclosed in its Form 10-K for the year ended December 31, 2011.

As of June 30, 2012, the majority of the Company's cash and cash equivalents were held outside of the United States. Most of these balances could be repatriated to the United States, however, under current law, would potentially be subject to U. S. federal income tax, less applicable foreign tax credits. Historically, the Company has generated more than sufficient operating cash flows in the United States to fund domestic operations. Further, the Company expects on an ongoing basis, to be able to finance domestic and international cash requirements, including capital expenditures, stock repurchases, debt service, operating leases and potential future acquisitions, from the funds generated from operations and amounts available under its existing credit facilities.

NEW ACCOUNTING PRONOUNCEMENTS

Refer to Note 1, Significant Accounting Policies, to the Unaudited Interim Consolidated Financial Statements for a discussion of recent accounting standards and pronouncements.

Item 3 - Quantitative and Qualitative Disclosures about Market Risk

There have been no significant material changes to the market risks as disclosed in the Company’s Form 10-K for the year ended December 31, 2011.

Item 4 - Controls and Procedures

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this report.  Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended) as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that it is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There have been no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.


47



PART II – OTHER INFORMATION

Item 1 - Legal Proceedings

Reference to Part I, Item 1, Note 15, Commitments and Contingencies, to the Unaudited Interim Consolidated Financial Statements.

Item 1A – Risk Factors

There have been no significant material changes to the risk factors as disclosed in the Company’s Form 10-K for the year ended December 31, 2011.

Item 2 - Unregistered Sales of Securities and Use of Proceeds

At June 30, 2012, the Company had authorization to maintain up to 34.0 million shares of treasury stock under the stock repurchase program as approved by the Board of Directors.  During the quarter ended June 30, 2012, the Company had the following activity with respect to this repurchase program:

(in thousands, except per share amounts)
 
 
 
 
 
 
Period
 
Total Number
of Shares
Purchased
 
Average Price
Paid Per
Share
 
Total Cost
of Shares
Purchased
 
Number of
Shares that
May be Purchased
Under the Share
Repurchase
Program
April 1, 2012
 
145.6

 
$
39.42

 
$
5,738.4

 
12,989.2

May 1, 2012
 
56.0

 
40.19

 
2,232.0

 
12,955.0

June 1, 2012
 

 

 

 
12,989.7

 
 
201.6

 
$
39.63

 
$
7,970.4

 
 


Item 4 - Submission of Matters to Vote of Security Holders

Reserved.

48



Item 6 - Exhibits

Exhibit Number
 
Description
10.14
 
Summary of Outside Director Compensation
31
 
Section 302 Certification Statements
32
 
Section 906 Certification Statements
101.INS
 
XBRL Instance Document
101.SCH
 
XBRL Taxonomy Extension Schema Document
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
 
XBRL Extension Labels Linkbase Document
101.PRE
  
XBRL Taxonomy Extension Presentation Linkbase Document

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DENTSPLY International Inc.

/s/
Bret W. Wise
 
July 31, 2012
 
Bret W. Wise
 
Date
 
Chairman of the Board and
 
 
 
Chief Executive Officer
 
 

/s/
William R. Jellison
 
July 31, 2012
 
William R. Jellison
 
Date
 
Senior Vice President and
 
 
 
Chief Financial Officer
 
 

49
Exhibit 10.14


Exhibit 10.14

SUMMARY OF OUTSIDE DIRECTOR COMPENSATION

Effective May 23, 2012, compensation paid to non-employee directors of the Company is as follows:

Cash Compensation

An annual cash retainer of $45,000, paid quarterly.
A fee of $1,500 for each board and committee meeting attended in person.
A fee of $1,000 for each board and committee meeting attended by telephone.
An annual retainer of $15,000 for the Lead Director; $15,000 for the Audit Committee Chair, $15,000 for the HR Committee Chair; and $10,000 for the Governance Committee Chair.

Outside directors may elect to defer their cash compensation under the Dentsply International Inc. Directors' Deferred Compensation Plan (as amended).

Equity Compensation

An annual grant of stock options to purchase a number of shares of common stock equal in value to $65,000, calculated using the Black-Sholes valuation method. The stock options vest in equal installments over a period of three years from the date of grant and have an exercise price equal to the closing price of the Company's common stock on the date of grant. Stock options are exercisable for ten years from the grant date, subject to earlier expiration in the event of termination or retirement.

An annual grant of restricted stock units (RSUs), the number of which is determined by dividing $65,000 by the closing price of the Company's common stock on the date of grant. The RSUs vest three years from the date of grant and are payable to outside directors in shares of common stock upon vesting unless the director elects to defer settlement of the RSUs to a future date. Outside directors are entitled to receive dividend equivalents on the RSUs in the event the Company pays a regular cash dividend on its common stock.




Exhibit 31 (1)

Exhibit 31.1

Section 302 Certifications Statement

I, Bret W. Wise, certify that:

1.
I have reviewed this Form 10-Q of DENTSPLY International Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: July 31, 2012

/s/
Bret W. Wise    
 
Bret W. Wise
 
Chairman of the Board and
 
Chief Executive Officer




Exhibit 31.2

Section 302 Certifications Statement

I, William R. Jellison, certify that:

1.
I have reviewed this Form 10-Q of DENTSPLY International Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: July 31, 2012

/s/
William R. Jellison
 
William R. Jellison
 
Senior Vice President and
 
Chief Financial Officer

Exhibit 32 (1)

Exhibit 32



CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of DENTSPLY International Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), We, Bret W. Wise, Chairman of the Board of Directors and Chief Executive Officer of the Company and William R. Jellison, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of our knowledge and belief:

(1)
The Report fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company as of the date of the Report.



/s/
Bret W. Wise    
 
Bret W. Wise
 
Chairman of the Board and
 
Chief Executive Officer


/s/
William R. Jellison
 
William R. Jellison
 
Senior Vice President and
 
Chief Financial Officer


July 31, 2012